<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Physiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Physiol</journal-id><journal-id journal-id-type="publisher-id">Front. Physiol.</journal-id><journal-title-group><journal-title>Frontiers in Physiology</journal-title></journal-title-group><issn pub-type="epub">1664-042X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5179568</article-id><article-id pub-id-type="doi">10.3389/fphys.2016.00635</article-id><article-categories><subj-group subj-group-type="heading"><subject>Physiology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Deep Phosphoproteomic Measurements Pinpointing Drug Induced Protective Mechanisms in Neuronal Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Chengli</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/396562/overview"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Yanting</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xiangling</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Ruoxuan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/399753/overview"/></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yansheng</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/298626/overview"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/352344/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Analytical Chemistry and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences</institution><country>Shanghai, China</country></aff><aff id="aff2"><sup>2</sup><institution>College of Pharmacy, University of Chinese Academy of Sciences, Chinese Academy of Sciences</institution><country>Beijing, China</country></aff><aff id="aff3"><sup>3</sup><institution>Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology</institution><country>Shanghai, China</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Biology, Institute of Molecular Systems Biology, Swiss Federal Institute of Technology in Zurich</institution><country>Zurich, Switzerland</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Xiaogang Wu, Institute for Systems Biology, USA</p></fn><fn fn-type="edited-by"><p>Reviewed by: Biswapriya Biswavas Misra, Texas Biomedical Research Institute, USA; Amit Kumar Yadav, Translational Health Science and Technology Institute, India</p></fn><corresp id="fn001">*Correspondence: Yansheng Liu <email xlink:type="simple">liu@imsb.biol.ethz.ch</email></corresp><corresp id="fn002">Hu Zhou <email xlink:type="simple">zhouhu@simm.ac.cn</email></corresp><fn fn-type="other" id="fn003"><p>This article was submitted to Systems Biology, a section of the journal Frontiers in Physiology</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>12</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><elocation-id>635</elocation-id><history><date date-type="received"><day>29</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>05</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#169; 2016 Yu, Gao, Zhou, Chen, Xiao, Zheng, Liu and Zhou.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Yu, Gao, Zhou, Chen, Xiao, Zheng, Liu and Zhou</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Alzheimer's disease (AD) is a progressive and irreversible neurological disorder that impairs the living quality of old population and even life spans. New compounds have shown potential inneuroprotective effects in AD, such as GFKP-19, a 2-pyrrolidone derivative which has been proved to enhance the memory of dysmnesia mouse. The molecular mechanisms remain to be established for these drug candidates. Large-scale phosphoproteomic approach has been evolved rapidly in the last several years, which holds the potential to provide a useful toolkit to understand cellular signaling underlying drug effects. To establish and test such a method, we accurately analyzed the deep quantitative phosphoproteome of the neuro-2a cells treated with and without GFKP-19 using triple SILAC labeling. A total of 14,761 Class I phosphosites were quantified between controls, damaged, and protected conditions using the high resolution mass spectrometry, with a decent inter-mass spectrometer reproducibility for even subtle regulatory events. Our data suggests that GFKP-19 can reverse A&#946;<sub>25&#8722;35</sub> induced phosphorylation change in neuro-2a cells, and might protect the neuron system in two ways: firstly, it may decrease oxidative damage and inflammation induced by NO via down regulating the phosphorylation of nitric oxide synthase NOS1 at S847; Secondly, it may decrease tau protein phosphorylation through down-regulating the phosphorylation level of MAPK14 at T180. All mass spectrometry data are available via ProteomeXchange with identifier PXD005312.</p></abstract><kwd-group><kwd>phosphoproteomics</kwd><kwd>Alzheimer's disease</kwd><kwd>drug effect</kwd><kwd>mass spectrometry</kwd><kwd>neutronal cells</kwd></kwd-group><counts><fig-count count="5"/><table-count count="0"/><equation-count count="0"/><ref-count count="87"/><page-count count="14"/><word-count count="9751"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Alzheimer's disease (AD) is a progressive and irreversible neurological disorder characterized by memory and cognitive impairment. AD is currently involved in 50&#8211;70% of dementia cases with half of people over 85 years of age suffering from it (Anand et al., <xref rid="B5" ref-type="bibr">2014</xref>; Imtiaz et al., <xref rid="B42" ref-type="bibr">2014</xref>). It is estimated that the prevalence of AD in year of 2050 would reach 88 million cases worldwide (Van Cauwenberghe and Van Broeckhoven, <xref rid="B81" ref-type="bibr">2016</xref>).</p><p>Among the medicines approved by the U.S. Food and Drug Administration (FDA), Donepezil, Galantamine, Reivastigmine, and Tacrine, for instance, are cholinesterase inhibitors dealing with the loss of cholinergic neurons (Amemori et al., <xref rid="B4" ref-type="bibr">2015</xref>), while memantine has the effect to block the cytotoxicity of excess extracellular glutamate on neurons as an N-Methyl-D-aspartate receptor (NMDAR) antagonist (Arbor et al., <xref rid="B6" ref-type="bibr">2016</xref>). It seems that most of the current therapeutic drugs for AD are designed to provide symptomatic treatment rather than to restore the declined brain function.</p><p>The two main neuropathological characteristics of AD have been recognized, namely senile plaques (SPs) and neurofibrillary tangles (NFTs), which are, respectively, associated to amyloid &#946; (A&#946;) peptides and hyperphosphorylated tau protein (Holtzman et al., <xref rid="B40" ref-type="bibr">2011</xref>; Marsden et al., <xref rid="B54" ref-type="bibr">2011</xref>). With important functional consequences in neurogenesis, amyloid precursor protein (APP) could be cleaved by &#946;-secretase at the N-terminal of an A&#946; sequence, and then cleaved by &#947;-secretase subsequently to produce an A&#946; fragment (De Strooper, <xref rid="B24" ref-type="bibr">2010</xref>). Among these key molecules, A&#946; is a peptide with 40~42 amino acids most commonly in length, aggregation of which could lead to NFTs, vascular damage, neuronal loss, and even dementia (Hardy and Higgins, <xref rid="B37" ref-type="bibr">1992</xref>). Tau is a microtubule-associated protein (MAP) necessary for stabilizing microtubules, and proper phosphorylation of tau within the microtubules is required for neurite outgrowth (Lindwall and Cole, <xref rid="B50" ref-type="bibr">1984</xref>; Caceres and Kosik, <xref rid="B13" ref-type="bibr">1990</xref>). Nevertheless, hyperphosphorylated tau has been validated in AD, which is able to further promote its dissociation from microtubules and thus resulting in protein destabilization and disruption of neuronal transport (Garcia and Cleveland, <xref rid="B32" ref-type="bibr">2001</xref>). Moreover, mitochondrial dysfunction has been found in multiple AD tissues (Swerdlow, <xref rid="B75" ref-type="bibr">2002</xref>). Accordingly the existing mitochondrial cascade hypothesis assumes that it is the brain mitochondrial dysfunction in AD that induce amyloidosis and tau phosphorylation (Swerdlow and Khan, <xref rid="B76" ref-type="bibr">2004</xref>). Furthermore, memory impairment and dementia are common symptoms of AD. Significant cholinergic dysfunctions in central nervous system of AD had been found. These studies, combined with the emerging role of cholinergic system (Drachman and Leavitt, <xref rid="B26" ref-type="bibr">1974</xref>), led to cholinergic hypothesis which proposes that cognitive disorder in patients with AD is dramatically associate to the loss of cholinergic neurons in the basal forebrain (Bartus et al., <xref rid="B8" ref-type="bibr">1982</xref>). Based on the above mechanisms, acetylcholinesterase (AChE) inhibitors, such as donepezil, galantamine, and rivastigmine and NMDAR antagonist like memantine have been common medicines for AD. Considering inflammation and oxidative damage are reported in AD (Galimberti and Scarpini, <xref rid="B31" ref-type="bibr">2011</xref>) and anti-inflammatory drugs and antioxidants have been made to slow the progression of AD (Cole and Frautschy, <xref rid="B18" ref-type="bibr">2010</xref>; Lee et al., <xref rid="B49" ref-type="bibr">2010</xref>).</p><p>With its high sensitivity, high accuracy and high selectivity recently achieved, mass spectrometry (MS) increasingly plays a vital role in biomarker discovery, pharmaceutical research, and in revealing molecular mechanisms of drug actions and activities (Aebersold and Mann, <xref rid="B2" ref-type="bibr">2003</xref>, <xref rid="B3" ref-type="bibr">2016</xref>). In the research field of AD, for example, Lynn et al. utilized a 2-dimensional liquid chromatography-tandem mass spectrometry (LC-MS/MS) and the isotope coded affinity tag (ICAT) method to identify, quantify and distinguish potentially interacting mitochondrial proteins in short postmortem temporal pole specimens with mild cognitive impairment, early AD, late-stage AD and age-matched normal control subjects (Lynn et al., <xref rid="B53" ref-type="bibr">2010</xref>). Similarly, an LC-MS/MS based approach was developed by Hejazi et al to investigate the content of sphingomyelin, ceramide, and galactosylceramide in hippocampus from AD and control subjects, which could be further applied for lipid analysis (Hejazi et al., <xref rid="B38" ref-type="bibr">2011</xref>). Also, Dillen et al. set up a screening UHPLC&#8211;MS/MS method for analysis of amyloid peptides in cerebrospinal fluid, thus laying foundation for the preclinical study (Dillen et al., <xref rid="B25" ref-type="bibr">2011</xref>). Currently, despite the development of label-free proteomic methods, the isotopic labeling methods still present the most accurate quantification approach, especially for those regulations with a small fold change (FC) (Walther et al., <xref rid="B84" ref-type="bibr">2015</xref>). Stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al., <xref rid="B61" ref-type="bibr">2002</xref>) is a powerful metabolic labeling strategy in MS-based quantitative proteomics, when combined with phosphoproteomics can provide efficient and robust help to test quantitative changes in phosphorylation sites (Dengjel et al., <xref rid="B22" ref-type="bibr">2007</xref>; Dephoure et al., <xref rid="B23" ref-type="bibr">2008</xref>; Hilger et al., <xref rid="B39" ref-type="bibr">2009</xref>). The combination of phosphoproteomics and SILAC labeling is therefore very promising to be tested for analyzing post-translational regulations in AD related research areas.</p><p>As an example, we selected GFKP-19, which is a 2-pyrrolidone derivative compound, and could be a promising drug candidate for AD treatment. The pyrrolidone derivative racetam drugs, such as aniracetam is an ampakine nootropic with glutamatergic activity and neuroprotective potential (Koliaki et al., <xref rid="B44" ref-type="bibr">2012</xref>). The 2-pyrrolidone clausenamideare is an anti-dementia drug candidate and been reported to inhibit the cytotoxicity of beta amyloid, tau hyperphosphorylation and neurodegeneration (Hu et al., <xref rid="B41" ref-type="bibr">2010</xref>; Chu and Zhang, <xref rid="B15" ref-type="bibr">2014</xref>; Chu et al., <xref rid="B16" ref-type="bibr">2016</xref>). To mimic the injury of neuron cells in AD, we used the active A&#946;<sub>25&#8722;35</sub> peptide (peptide containing the 25&#8211;35 th amino acids of A&#946;). A&#946;<sub>25&#8722;35</sub> peptide exhibits the similar cytotoxic properties of the full-length protein A&#946;<sub>1&#8722;42</sub>, and has been reported to be the active fragment of A&#946;<sub>1&#8722;42</sub> (Pike et al., <xref rid="B66" ref-type="bibr">1995</xref>; Clementi et al., <xref rid="B17" ref-type="bibr">2005</xref>). In previous studies, A&#946;<sub>25&#8722;35</sub> treatment can induce apoptosis in many mammalian cell lines <italic>in vitro</italic>. To determine if GFKP-19 can remit A&#946;<sub>25&#8722;35</sub> induced effect and the mechanisms underlying its neuroprotective effects, we carried out a phosphoproteomic study measuring the cellular signaling changes in different states of neuro-2a cell by DMSO, A&#946;<sub>25&#8722;35</sub> alone or A&#946;<sub>25&#8722;35</sub> together with GFKP-19 treatment. The phosphorylation of tau increased after A&#946;<sub>25&#8722;35</sub> treatment, and the increase can be reversed by GFKP-19. Interestingly, the changes in the phosphorylation of tau kinases also increased during A&#946;<sub>25&#8722;35</sub> treatment and decreased with the addition of GFKP-19. The comprehensive profiling of phosphorylation regulation events by SILAC and MS provides a general framework for understanding drug actions, which is for the first time reported for the AD relevant drug candidate compounds.</p></sec><sec sec-type="materials and methods" id="s2"><title>Materials and methods</title><sec><title>Materials</title><p>A&#946;<sub>25&#8722;35</sub> was purchased from Sigma (Sigma, A4559). N2 supplement was purchased from Gibco (Gibco, 17502048). As an example of 2-pyrrolidone derivative compounds GFKP-19 was kindly provided by a collaboration laboratory, which wishes to not release the detailed structure of this compound along with the present paper. A&#946;<sub>25&#8722;35</sub> was dissolved in DMSO at a concentration of 3 mM. GFKP-19 was dissolved in DMSO at a concentration of 10 mM. 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium bromide (MTT) was purchased from MP Biomedicals (MP Biomedicals, 02102227). The dialyzed fetal bovine serum (FBS) was from Hyclone (Hyclone, SH30079.03). The Amicon Ultra 15 mL centrifugal filter with a membrane NMWL of 30 kDa was purchased from Merck Millipore (Merck Millipore, UFC903024).</p></sec><sec><title>Cell culture</title><p>Neuro-2a cells purchased from American Type Culture Collection (ATCC, CCL-131) were cultured in DMEM media supplemented with 10% FBS, 1% penicillin/streptomycin, growing in humidified incubator at 37&#176;C and 5% CO<sub>2</sub>. N2 supplement (Gibco, 17502048) was used as a serum-free supplement during drug treatment. Neuro-2a cells were evenly seeded into 96-well plates with a density of 5 &#215; 10<sup>3</sup> cells per well. At the second day, cells were pretreated with or without GFKP-19 (0.1 or 1 &#956;M) for 1 h, and A&#946;<sub>25&#8722;35</sub> (1 &#956;M) was added in the presence of GFKP-19 and all cells were incubated for another 24 h. Control cells were treated with corresponding concentration of DMSO.</p></sec><sec><title>Determination of cell viability</title><p>Cell viability was measured by MTT assays (Mosmann, <xref rid="B60" ref-type="bibr">1983</xref>; Ulukaya et al., <xref rid="B80" ref-type="bibr">2004</xref>). After treatments above, cells were incubated with 0.5 mg/mL MTT for 4 h. Then, the supernatant was removed carefully and 150 &#956;L DMSO was added to dissolve the formazan. The plate was shaken for 10 min, and absorbance at 490 nm was obtained with a microplate reader (BIO-RAD Model 3550).</p></sec><sec><title>SILAC labeling and sample preparation</title><p>DMEM media for SILAC (Thermo, 89985) was supplemented with 10% dialyzed FBS, 1% penicillin/streptomycin and before drug treatment, and the dialyzed FBS was replaced by N2 supplement during drug treatment. The light SILAC amino acids L-lysine (Sigma, L8662) and L-arginine (Sigma, A8094), the medium SILAC amino acids L-lysine-<sup>2</sup>H<sub>4</sub> (Sigma, 616192) and L-arginine-<sup>13</sup>C<sub>6</sub> (Sigma, 643440), or the heavy SILAC amino acids L-lysine-<sup>13</sup><inline-formula><mml:math id="M1"><mml:mrow><mml:msubsup><mml:mtext>C</mml:mtext><mml:mn>6</mml:mn><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>N<sub>2</sub> (Sigma, 608041) and L-arginine-<sup>13</sup><inline-formula><mml:math id="M2"><mml:mrow><mml:msubsup><mml:mtext>C</mml:mtext><mml:mn>6</mml:mn><mml:mrow><mml:mn>15</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>N<sub>4</sub> (Sigma, 608033) were added with a final concentration of 28 mg/L for the arginine and 50 mg/L for the lysine amino acids to generate light, medium, and heavy SILAC-labeling media. Neuro-2a cells were labeled as previously published with light, medium and heavy SILAC-labeling media (Ong and Mann, <xref rid="B62" ref-type="bibr">2006</xref>). After eight passages, full incorporation of SILAC amino acid was confirmed.</p><p>Light SILAC-labeling cells were taken as controls, whereas medium SILAC-labeling cells were treated with A&#946;<sub>25&#8722;35</sub> (1 &#956;M) for 4 or 24 h, and heavy SILAC-labeling cells were pretreated with GFKP-19 for 1 h followed exposure to A&#946;<sub>25&#8722;35</sub> (1 &#956;M) and GFKP-19 for another 4 or 24 h. All cells were, respectively, lysed in buffer containing 4% SDS, 0.1M DTT, 100 mM tris (pH 7.5). The protein concentrations were evaluated by tryptophan fluorescence emission assay (Kulak et al., <xref rid="B45" ref-type="bibr">2014</xref>) and evaluated by SDS-polyacrylamide gel electrophresis (SDS-PAGE). 100 ng/&#956;L tryptophan was used to build a standard calibration curve (0, 0.125, 0.25, 0.5, 0.75, 100, and 150 &#956;L), and 1 &#956;L of sample was diluted in 200 &#956;L of 8 M urea for reading protein amount. An excitation wavelength of 295 nm was adopted to determine protein concentrations whereby tryptophan fluorescence emission at 350 nm. The assaying instrument used was SpectraMax M5 (Molecular Devices, Sunnyvale, CA). Protein extracts derived from different treatments were then mixed at the ratio of 1:1:1 at the protein level. A total of 15 mg protein mixture was alkylated with iodoacetamide and digested by trypsin following the filiter-aided sample preparation method (FASP) reported (Wisniewski et al., <xref rid="B86" ref-type="bibr">2009</xref>). The enzymatic hydrolysis efficiency was around 40~50%. The peptides were subjected to TiO<sub>2</sub> enrichment to get phosphopeptides as described below.</p></sec><sec><title>TiO<sub>2</sub> enrichment of phosphopeptides</title><p>Phosphopeptides were enriched by using Titansphere-chromatography (TiO<sub>2</sub>) as described (Thingholm et al., <xref rid="B77" ref-type="bibr">2006</xref>; Selenica et al., <xref rid="B73" ref-type="bibr">2007</xref>) with minor modifications. Briefly, 1 mg of slurry of 5 &#956;m Titansphere material (GL Sciences) in 80% ACN/1% TFA containing saturated glutamic acid was added directly to the 1 mg tryptic peptides. The slurry was incubated for 15&#8211;30 min at room temperature with end-over-end rotation, spunbriefly on a bench-top centrifuge, and the supernatant was collected. Titansphere material with phosphopeptides bounded was washed two times with 400 &#956;L 30% ACN/0.5% TFA and 2 times with 400 &#956;L 70% ACN/0.1% TFA, then transferred on top of a C8 disc (Empore) placed in 200 &#956;L pipette-tip. Bound phosphopeptides were eluted by passing 1 times 50 &#956;L 0.6% NH<sub>4</sub>OH/20% ACN and 2 times 50 &#956;L 1% NH<sub>4</sub>OH/40% ACN through the beads. Elutes were then dried almost to completeness. Normally the yield is 1% of the original peptides input. All phosphopeptides got at this step were subjected to fractionation.</p></sec><sec><title>Phosphopeptide fractionation by high-pH reversed-phase LC</title><p>Samples were separated by high-pH reversed-phase high-performance liquid chromatography (HPLC). The fractionation procedure was modified from previously described protocol (Batth et al., <xref rid="B9" ref-type="bibr">2014</xref>). A Waters Xbridge BEH C18 2.5 &#956;m 3.0 &#215; 100 mm XP column and an Agilent 1290 HPLC were used. Mobile phase A: 10 mM ammonium formate, 100% H<sub>2</sub>O (adjusted to pH 10 with ammonium hydroxide); B: 10 mM ammonium formate, 10% H<sub>2</sub>O, 90% ACN (adjusted to pH 10 with ammonium hydroxide). Dried phosphopeptides were dissolved in mobile phase A. The temperature of the column was operated at 45&#176;C. After loaded onto the column, samples were separated using a 66 min gradient at a flow rate of 200 &#956;L/min, as follows: 0 min 5% B; 50 min 25% B; 54 min 60% B; 56 min 70% B; 61 min 70% B; 63 min 5% B; 66 min 5% B. All fractions were collected at 2 min intervals. 28 fractions were collected between 0 and 56 min and were pooled into 14 fractions by combining fractions (1 and 15 were combined as fraction 1; 2 and 16 were combined as fraction 2; 3 and 17 were combined as fraction 3, and so on, until 14 and 28 as fraction 14).</p></sec><sec><title>LC-MS/MS analysis</title><p>All LC-MS/MS analysis were performed on an EASY n-LC 1000 system directly connected to a Q Exactive (Thermo Fisher Scientific, San Jose, CA) or a Q Exactive HF (Thermo Fisher Scientific, San Jose, CA) mass spectrometer which equipped with a nanospray ion source. Phosphopeptide fractions were dissolved in solvent A (0.1% formic acid, 100% H<sub>2</sub>O) and loaded onto a reversed-phase column, which was packed in-house with 3 &#956;m C18 ReproSil particles (Dr. Maisch GmbH). The inner diameter of the column was 75 &#956;m. The solvent B was 0.1% formic acid in acetonitrile. Samples were separated with a 2 h gradient at a flow rate of 300 nL/min. The gradient was set up as follows: 0&#8211;4 min, 3&#8211;4% B; 106 min, 20% B; 114 min, 35% B; 117&#8211;120 min, 90% B. Each sample was analyzed twice by Q Exactive or Q Exactive HF, respectively.</p><p>For Q Exactive, the instrument parameters were set as: The scan range was between 300 and 1500 m/z and full scan resolution was set at 70,000; fragmentation was performed with the high-energy collisional dissociation (HCD) with a normalized collision energy (NCE) of 28%; one full scan was followed by 15 data-dependent MS/MS scans with a resolution of 17,500 and isolation window of 2.0 m/z.</p><p>For Q Exactive HF, the instrument parameters were as follows: The full scan used a mass window of 350&#8211;1800 m/z at a target resolution of 60,000; precursor ions were fragmented by HCD with a NCE of 27%; one full scan was followed by 20 data-dependent MS/MS scans with a resolution of 30,000 and isolation window of 1.6 m/z.</p><p>The MS parameters are firstly set up according to the vender's instructions and then optimized in house to maximize the analytical power of each machine.</p></sec><sec><title>Data analysis</title><p>The raw data files were processed using software MaxQuant (Cox and Mann, <xref rid="B19" ref-type="bibr">2008</xref>) version 1.5.1.0 with an false-discovery rater (FDR) &lt;0.01 at all the levels of proteins, peptides and modifications, to generate peak lists. The MS/MS spectra were searched against the Mouse UniProt FASTA database (July 2016) containing 51418 entries. Enzyme specificity was set to trypsin, allowing for cleavage N-terminal to proline and between aspartic acid and proline. The search included cysteine carbamidomethylation as a fixed modification and N-acetylation of protein, oxidation of methionine and/or phosphorylation of serine, threonine tyrosine residue (STY) as variable modifications. The missed cleavage number allowed was set as no more than 3. The SILAC based quantification of peptides and proteins was also performed by MaxQuant. SILAC ratios were normalized so that the median ratio was 1 to correct unequal sample mixing. Bioinformatics analyses were carried out with Microsoft Excel, GraphPad, Perseus (Tyanova et al., <xref rid="B79" ref-type="bibr">2016</xref>), and R (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org/">https://www.r-project.org/</ext-link>) statistical computing software. Functional annotations were made through UniProtKB (<ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org/uniprot/">http://www.uniprot.org/uniprot/</ext-link>), the Database for Annotation, Visualization and Integrated Discovery (DAVID) (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/">https://david.ncifcrf.gov/</ext-link>), motif-x (Schwartz and Gygi, <xref rid="B72" ref-type="bibr">2005</xref>), and Ingenuity Pathway Analysis (IPA, version 8.5, Ingenuity Systems, Redwood City, CA). Interaction network was made with software Cytoscape (<ext-link ext-link-type="uri" xlink:href="http://www.cytoscape.org">http://www.cytoscape.org</ext-link>) and the physical interaction was provided by the SIGnaling Network Open Resource (SIGNOR) (Perfetto et al., <xref rid="B64" ref-type="bibr">2016</xref>). Categorical annotation was performed in the Perseus software environment (Tyanova et al., <xref rid="B79" ref-type="bibr">2016</xref>), which is a following up analysis tool in MaxQuant workflow. Categorical annotation was supplied in the form of GO biological process, molecular function, and cellular component. Enrichment for these categories was evaluated by Fisher exact test. Multiple hypothesis testing was controlled by using a Benjamini-Hochberg FDR threshold of 0.02. The annotation matrix algorithm was used to compute the difference of any significant protein annotation term from the overall intensity distribution as described (Cox et al., <xref rid="B20" ref-type="bibr">2012</xref>). Motif-X was used to test for significantly overrepresented motifs, with the following parameters: <italic>P-</italic>value threshold &#8804; 1.0E-6, with the entire mouse database as background database. The fold increase of motif was visualized with the Pheatmap package in R.</p></sec></sec><sec id="s3"><title>Results and discussions</title><sec><title>GFKP-19 suppresses the A&#946;<sub>25&#8722;35</sub> induced cytotoxicity in neuro-2a</title><p>To determine whether GFKP-19 can protect neuro-2a cells (a brain neuroblastoma cell line) against the cytotoxicity induced by A&#946;<sub>25&#8722;35</sub>, neuro-2a cells were treated with 1 &#956;M A&#946;<sub>25&#8722;35</sub> in the absence or presence of GFKP-19 at different doses. When treated with GFKP-19 and A&#946;<sub>25&#8722;35</sub>, cells were pretreated with GFKP-19 for 1 h before A&#946;<sub>25&#8722;35</sub> was added in. According to cell viability assayed by MTT method, the applicable concentration of A&#946;<sub>25&#8722;35</sub> was decided according to the results of prevent experiments (Figure <xref ref-type="supplementary-material" rid="SM3">S1A</xref>) and previous report (Shih et al., <xref rid="B74" ref-type="bibr">2011</xref>). Furthermore, we found that the treatment with A&#946;<sub>25&#8722;35</sub> significantly decreased cell viability as assessed, and GFKP-19 was able to reverse the change (Figure <xref ref-type="fig" rid="F1">1A</xref> and Figure <xref ref-type="supplementary-material" rid="SM3">S1B</xref>). Thus, the above cell viability measurements qualified the samples for further proteomic analysis.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Schematic overview of experiment. (A)</bold> GFKP-19 can reverse the cytotoxic effect of A&#946;<sub>25&#8722;35</sub> in neuro-2a. Determination of the cell viability of Neuro-2a after treatment with A&#946;<sub>25&#8722;35</sub> in the absence or presence of GFKP-19 was carried out cells by MTT assay. Neuro-2a cells were exposed to different concentrations of GFKP-19 (0, 0.1, 1 &#956;M) combined with 1 &#956;M A&#946;<sub>25&#8722;35</sub> for 24 h. The cell viability was determined by MTT assay (<italic>n</italic> = 5, <sup>**</sup><italic>P</italic> &lt; 0.01 vs. control, <sup><italic>##</italic></sup><italic>P</italic> &lt; 0.01 vs. A&#946;<sub>25&#8722;35</sub>-treated group). <bold>(B)</bold> Flow diagram of the SILAC-based quantitative phosphoproteomics analysis. Neuro-2a cells cultured in light, medium and heavy SILAC-labeling media was severally treated with DMSO as control, A&#946;<sub>25&#8722;35</sub> (1 &#956;M) or A&#946;<sub>25&#8722;35</sub> (1 &#956;M) combined with GFKP-19 (1 &#956;M) for 4 or 24 h. Cell lysates to be compared were mixed, trypsin digested using filter-aided sample preparation (FASP), enriched on TiO<sub>2</sub> beads to obtain phosphopeptides, fractionated with high pH reversed-phase and analyzed by online LC-MS/MS. Q Exactive and Q Exactive HF were used. <bold>(C)</bold> Overview of the LC-MS/MS results.</p></caption><graphic xlink:href="fphys-07-00635-g0001"/></fig></sec><sec><title>Quantitative and comprehensive phosphoproteome analysis in neuro-2a cells</title><p>To gain global insight into the protective mechanism of GFKP-19, we combined the quantification method SILAC, high-pH reversed phase HPLC for fractionation, TiO<sub>2</sub> chromatography for phosphopeptide enrichment and high accuracy mass spectrometry characterization (Figure <xref ref-type="fig" rid="F1">1B</xref> and Methods). The study was carried out on neuro-2a cells, which were cultured in light, medium and heavy SILAC-labeling media paralleling three different treatment conditions selected based on the cytotoxicity experiments (DMSO, 1 &#956;M A&#946;<sub>25&#8722;35</sub>, 1 &#956;M A&#946;<sub>25&#8722;35</sub> + 1 &#956;M GFKP-19). After treated with drugs for 4 or 24 h, cells were lysed and the proteins were mixed at the ratio of 1:1:1 and digested by trypsin with the method FASP. Subsequently, peptides were incubated with TiO<sub>2</sub> and phosphopeptides were enriched. Next, phosphopeptides of each sample were separated into 14 fractions to decrease the complexity of the samples. The light, medium and heavy stable isotope labeled phosphopeptides were detected with highly accurate LC-MS/MS which incorporates a nanoLC system and a Q Exactive (QE) or a Q Exactive HF (HF). QE is a high-performance quadrupole Orbitrap mass spectrometer (Michalski et al., <xref rid="B58" ref-type="bibr">2011</xref>) and HF denotes the improved version of QE which feature several innovations (Scheltema et al., <xref rid="B70" ref-type="bibr">2014</xref>). Mass spectrometric data generated from QE and HF of three experiment groups was searched in MaxQuant using rigorous criteria. Totally, 25715 phosphosites were identified, corresponding to 5221 phosphoproteins. Among them, 18505 Class I phosphosites (of which localization probability is at least 0.75 and the score difference is 5 or higher, Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>) (Pan et al., <xref rid="B63" ref-type="bibr">2009</xref>) were identified and 14761 of them (that is, 80%) were quantified (Figure <xref ref-type="fig" rid="F1">1C</xref>).</p><p>Next, we analyzed the coverage of cellular functions of the deep phosphoproteome measured. To do so, we compared the Gene Ontology (GO) annotation for cellular compartment between murine genome and identified phosphoproteins in neuro-2a cells. GO cellular component analysis, using DAVID, revealed organelle, cytoplasm, nucleus, cytoskeleton, chromosome, chromatin, endosome and vesicle to be overrepresented, indicating that the functions of these parts of cells are based on significant phosphorylation. As expected, extracellular proteins in membrane, focal adhesion and extracellular region were underrepresented (Figure <xref ref-type="fig" rid="F2">2A</xref>). This is in agreement with previous reports proving low phosphorylation in the extracellular matrix (Weintz et al., <xref rid="B85" ref-type="bibr">2010</xref>). The phosphoproteins identified were classified with Ingenuity IPA for protein class analysis (Figure <xref ref-type="fig" rid="F2">2B</xref>). These results suggest the phosphoproteome reflected essential biological functions, such as kinase (<italic>N</italic> = 344), phosphatase (<italic>N</italic> = 99), transcription regulators (<italic>N</italic> = 649) and other processes and their regulations between conditions, demonstrating the direct relevance of studying phosphoproteome in A&#946; cytotoxicity.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>The fractionated phosphopeptides were analyzed by an EASY n-LC 1000 system directly connected to a Q Exactive (QE) or a Q Exactive HF (HF). (A)</bold> Distribution of phosphoproteins identified in cells. Identified phosphorylation proteins were assigned to DAVID GO terms for cellular component. Numbers of proteins belonging to each GO term are demonstrated as percentages of the total number of proteins. GO terms significantly over- and under-represented are marked [fold enrichment &#8805; 1.4 or &#8804; 0.67, <italic>P</italic> &#8804; 0.01 (<sup>**</sup>)]. <bold>(B)</bold> Function classification of phosphoproteins identified. The sorting was done with Ingenuity IPA and the bar plot was generated with GraphPad. <bold>(C)</bold> Scatter plots of the log-transformed ratios A&#946;<sub>25&#8722;35</sub>/Control (Ab vs. Con), (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/Control (GF vs. Con), and (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/A&#946;<sub>25&#8722;35</sub> (GF vs. Ab) demonstrate the correlation between QE results and HF results. Black dash lines represent 1.5 FC. The correlation coefficient (R) were calculated using spearman.</p></caption><graphic xlink:href="fphys-07-00635-g0002"/></fig></sec><sec><title>Analysis of global extent of phosphoproteomic regulation</title><p>We then focused on the quantified phosphoproteomic regulation. Benefiting from the fact that the experimental replicates were performed at two independent mass spectrometers and analyzed separately, we first correlated the ratios A&#946;<sub>25&#8722;35</sub>/Control (Ab vs. Con), (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/Control (GF vs. Con) and (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/A&#946;<sub>25&#8722;35</sub> (GF vs. Ab) obtained from two mass spectrometer (QE and HF). We concluded three important points in our biological and experimental system. <italic>Firstly</italic>, the global regulation of phosphoproteome is minor between conditions, because the fold-changes (FCs) of majority (&gt;90%) of the phosphosites remained below 1.5 FCs. Also, GF vs. Con at 4 h only have minor change suggesting that GFKP-19 has small effect on normal neuro-2a cells. This validates our experimental approach where specific, rather than broad, phosphoprotein regulations (e.g., those triggered by cell death) were captured. <italic>Secondly</italic>, we found the correlations of A&#946;<sub>25&#8722;35</sub>/Control (Ab vs. Con) and (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/Control (GF vs. Con), as well as the numbers of significantly regulated phosphorylation events were both higher at 4 h compared to those of 24 h (Figure <xref ref-type="fig" rid="F2">2C</xref>). For the 4 h data of QE and HF, 5.5 and 6.3% of the phosphosites have the FC of Ab vs. Con at least 1.5; 1.3 and 2.0% of the phosphosites have the FC of GF vs. Con at least 1.5; 4.0 and 4.7% of the phosphosites have the FC of GF vs. Ab at least 1.5. For the 24 h data of QE and HF, 2.1 and 2.7% of the phosphosites have the FC of Ab vs. Con at least 1.5; 1.2 and 1.3% of the phosphosites have the FC of GF vs. Con at least 1.5; 1.0 and 1.5% of the phosphosites have the FC of GF vs. Ab at least 1.5. This means that 4 h is a good time point to inspect phosphorylation regulation, while the status at 24 h only have minor phosphoproteomic changes. This is consistent to the rapid responsive role of phosphorylation in cellular systems (Roux and Thibault, <xref rid="B68" ref-type="bibr">2013</xref>). <italic>Last but not the least</italic>, we managed to obtain overall decent correlations between the data sets generated from the two mass spectrometers, despite of the global phosphoproteomic changes were minor. The correlation of the repeat experiments between QE and HF can be seen in Figure <xref ref-type="supplementary-material" rid="SM3">S2A</xref>. As expected, HF, which has the higher instrumental configuration, generated a larger data set compared to QE (Figure <xref ref-type="supplementary-material" rid="SM3">S2B</xref>). The biological compositions of phosphoproteome reflected by the two instruments are also very consistent. Just as an example, for the 4 h data of QE, identified phosphosites of class I sites consist of 88.3% phosphor-Ser sites, 11.2% phosphor-Thr sites, and 0.5% phosphor-Tyr sites; for the 4 h data of HF, most phosphosites of class I sites were on Ser (88.1%) and Thr (11.0%), whereas 0.8% phosphosites were at Tyr (Figure <xref ref-type="supplementary-material" rid="SM3">S2C</xref>). The high inter-instrument correlation essentially provides a benchmark for our quantification data, suggesting the phosphoproteomic regulations, although they were mostly of &lt;1.5 FCs, are not due to experimental noise. To summarize, our integrative method captured the phosphoproteomic snapshots at two time points between three conditions (Ab vs. Con, GF vs. Con, and GF vs. Ab), revealing phosphoproteome regulations are globally of a small extent but biologically specific.</p></sec><sec><title>Significant protein phosphorylation regulated by A&#946;<sub>25&#8722;35</sub> and GFKP-19 and their patterns</title><p>Given the relatively slow and mild effects on nerve cells of neuron protective drugs, we set a filter criteria to better understand the proteins whose phosphorylation were regulated by A&#946;<sub>25&#8722;35</sub> and GFKP-19. This is because we hypothesize the more significantly regulated phosphoproteome events are more closely related to A&#946; cytotoxicity and the protective mechanisms of GFKP-19. The substantially changed phosphosites were screened as follows: <italic>first</italic>, for both Con vs. Ab and GF vs. Ab, at least one of twice the FC up than 1.5 was quantified by QE or HF; <italic>second</italic>, both Con vs. Ab and GF vs. Ab undergo FC at least 1.5 or one of them experience more than 1.2 FCs and another at least 1.5 FCs (Figure <xref ref-type="fig" rid="F3">3A</xref>, Table <xref ref-type="supplementary-material" rid="SM2">S2</xref>). These highlighted phosphosites could be critical to GFKP-19 function in response to the cell toxicity of A&#946;<sub>25&#8722;35</sub>, and analysis with heat map show very small change in GF vs. Con and opposite change between Ab vs. Con and GF vs. Ab (Figure <xref ref-type="supplementary-material" rid="SM3">S3</xref>). To interrogate which cell function the filtered phosphosites participate in, GO annotation enrichment for cellular function of the phosphoproteins was done. Notably, cellular function like cytoskeleton protein binding, tubulin binding, microtubule binding, cell projection, cell junction have been enriched (Benjamini-Hochberg FDR threshold of 0.02 for all processes, Figure <xref ref-type="fig" rid="F3">3B</xref>). Tau plays a vital role in the microtubule assembly and stability. Main post-translational modification of tau is phosphorylation which results in tau aggregation in pathological situations (Avila et al., <xref rid="B7" ref-type="bibr">2004</xref>). Neuron morphology is formed by cytoskeletal scaffolding. Hyperphosphorylation of tau is a premise for its aberrant aggregation and the formation of NFTs, which is a main neuropathological characteristic of AD. All of this suggests that A&#946;<sub>25&#8722;35</sub> and GFKP-19 treatment related to the cell function that involved in AD progression.</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Quantitative proteomics reveals protein phosphorylation regulated by A&#946;<sub><bold>25&#8722;35</bold></sub> and GFKP-19. (A)</bold> Screening changed phosphosites with the standard: both Con vs. Ab and GF vs. Ab undergo FC at least 1.5 or one of them experience more than 1.2 FC and another at least 1.5 FC. Phosphosites identified using QE and HF with FC meeting demand were drew as blue circles and the remaining phosphosites were drew as black circles. Black dash lines represent 1.5 FC and gray dash lines represent 1.2 FC. <bold>(B)</bold> GO annotation enrichment of the phosphoproteins corresponding to the changed phosphosites.</p></caption><graphic xlink:href="fphys-07-00635-g0003"/></fig><p>To acquire a broad understand of the phosphorylation sites and their sequence pattern significantly changed in experiment group Ab vs. Con, GF vs. Con and GF vs. Ab, we carried out motif enrichment with motif-x (Schwartz and Gygi, <xref rid="B72" ref-type="bibr">2005</xref>) with a <italic>P</italic>-value of &#8804; 1.0E-6. The analysis was done separately to the phosphopeptides that were up regulated or down regulated in Ab vs. Con, GF vs. Con and GF vs. Ab (Figure <xref ref-type="supplementary-material" rid="SM3">S4</xref>). More motifs were enriched for down regulated phosphosites of GF vs. Ab. Taking focus on the results of GF vs. Ab (Figure <xref ref-type="fig" rid="F4">4A</xref>), in the phosphosites up regulated we found an enrichment of proline-directed (phosphor-Ser-X-X-X-phospho-Ser-Pro), basophilic (Arg-phospho-Ser-X-phospho-Ser and Arg-X-X-phospho-Ser-X-X-X-phospho-Ser), and basophilic at left and basophilic at right (Arg-X-X-phospho-Ser-X-Asp) motifs, whereas the phosphosites down regulated were enriched for basophilic and proline-directed (phosphor-Ser-Pro-X-X-X-Arg) motif (Figure <xref ref-type="fig" rid="F4">4B</xref>). The phosphorylation of proteins with these motifs can possibly be regulated by A&#946;<sub>25&#8722;35</sub> and GFKP-19. Further experiments are needed to verify the functional relevance of AD for these phosphopeptide motif patterns.</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Motif analysis. (A)</bold> Motif analysis of phosphopeptides significantly changed in GF vs. Ab. Binary logarithm of the motif fold increase was used. Greater fold change is displayed with deeper color. <bold>(B)</bold> Six enriched phosphosites motifs picked up from <bold>(A)</bold>.</p></caption><graphic xlink:href="fphys-07-00635-g0004"/></fig></sec><sec><title>GFKP-19 potentially regulates phosphorylation of tau</title><p>How does GFKP-19 protect neuro-2a cells from the cytotoxicity of A&#946;<sub>25&#8722;35</sub>? &#946;-Amyloid developing SPs in AD brain can lead to the generation of superoxide radicals which react with nitric oxide (NO) producing peroxynitrite and induces cell injury subsequently. Meanwhile, NO has been suggested to be associated to the pathogenesis of AD (Law et al., <xref rid="B47" ref-type="bibr">2001</xref>). NO is a free radical and can bind to superoxide anions to form peroxynitrite (Eliasson et al., <xref rid="B28" ref-type="bibr">1999</xref>), causing significant oxidative stress. NO is produced by nitric oxide synthase (NOS) which has three isoforms NOS1, NOS2, and NOS3. Overexpression of all three isoforms of NOS is significantly involved in AD and the initiation of the early progression of disease (de la Monte and Wands, <xref rid="B21" ref-type="bibr">2006</xref>). Phosphorylation of NOS1 at S852 activates NOS1 then increases NO production and protein phosphatase PP2B can dephosphorylate NOS1 at S852 (Foster et al., <xref rid="B30" ref-type="bibr">2009</xref>). We found the phosphorylation of NOS1 at S847, which is corresponding to S852 at human NOS1, is decreased by A&#946;<sub>25&#8722;35</sub> treatment and rescued with GFKP-19 (Table <xref ref-type="supplementary-material" rid="SM2">S2</xref>). This suggests that GFKP-19 may bring down the oxidative damage and inflammation induced by NO through suppressing its synthase NOS1.</p><p>Apoptosis-stimulating protein of p53 (ASPP2; encoded by the Tp53bp2 gene) has been identified as an activator of the p53 family. ASPP2 stimulates tumor suppressor protein p53-mediated apoptotic response (Samuels-Lev et al., <xref rid="B69" ref-type="bibr">2001</xref>; Bergamaschi et al., <xref rid="B10" ref-type="bibr">2004</xref>). ASPP2 can be phosphorylated at S827 by the RAS/MAPK pathway which increases its binding to p53 and enhances the transcription function of p53 (Godin-Heymann et al., <xref rid="B33" ref-type="bibr">2013</xref>). In our study, the phosphorylation of ASPP2 at S479 was detected to increase when treated with A&#946;<sub>25&#8722;35</sub> and was reversed with GFKP-19 treatment (Table <xref ref-type="supplementary-material" rid="SM2">S2</xref>). The site of S479 has been identified in previous report (Mertins et al., <xref rid="B57" ref-type="bibr">2014</xref>), but the extract relationship between the ASPP2 protein function and this phosphosite is still unknown.</p><p>As we know, NFTs induced by hyperphosphorylation of tau protein is one of the main neuropathological characteristics of AD and has been a direction of AD treatment. Pre-clinical studies on small molecule inhibitors of primary kinases involved in tau phosphorylation to prevent hyperphosphorylation of tau have shown promise (Khlistunova et al., <xref rid="B43" ref-type="bibr">2007</xref>; Pickhardt et al., <xref rid="B65" ref-type="bibr">2007</xref>). According to previous study, there are six isoforms of tau in human central nervous system (CNS) ringing in size from 352 to 441 amino acids, which generated by alternative splicing (Hanger et al., <xref rid="B36" ref-type="bibr">2009</xref>). Many kinases have been proved to be tau kinases in earlier investigations (V&#225;zquez-Higuera et al., <xref rid="B82" ref-type="bibr">2011</xref>; Martin et al., <xref rid="B55" ref-type="bibr">2013</xref>). To identify the targets of these tau kinases, large-scale studies aimed at determining phosphosites were done, and produced much information as reference. Proline-directed protein kinases of tau target Ser and Thr preceding a Pro residue (SP/TP motif). Mitogen-activated protein kinases (MAPK), such as p38 is contained in proline-directed protein kinases (Martin et al., <xref rid="B55" ref-type="bibr">2013</xref>).</p><p>In our results, 20 tau phosphosites were quantified and six of them showed up regulation after A&#946;<sub>25&#8722;35</sub> treated in line with previous reports that A&#946; fibrils can increase tau phosphorylation (Busciglio et al., <xref rid="B12" ref-type="bibr">1995</xref>), and down regulated with GFKP-19 treatment. The six phosphosites are S491, T523, S648, S688, S692, and S696 (Figure <xref ref-type="fig" rid="F5">5A</xref>, Figure <xref ref-type="supplementary-material" rid="SM3">S5</xref>, and Table <xref ref-type="supplementary-material" rid="SM3">S3</xref>), consistent to the phosphosites S199, T231, S356, S396, S400, and S404 in human tau isoform which had been reported before (Evans et al., <xref rid="B29" ref-type="bibr">2000</xref>; Thornton et al., <xref rid="B78" ref-type="bibr">2011</xref>; Luo et al., <xref rid="B52" ref-type="bibr">2014</xref>). The phosphorylation of at S199 residue of tau is enriched in section of neurons vulnerable to neurodegeneration and is an early marker of tau pathology (Maurage et al., <xref rid="B56" ref-type="bibr">2003</xref>). Phosphorylation at T231 has been assumed an initiating event for the formation of NFTs and NFTs induce neuronal cell death (Lasagna-Reeves et al., <xref rid="B46" ref-type="bibr">2012</xref>). The serine 356 site located in KXGS motif promote tau disconnection from microtubules which was probably a key site refer to AD (Abraha et al., <xref rid="B1" ref-type="bibr">2000</xref>; Haase et al., <xref rid="B35" ref-type="bibr">2004</xref>). The phosphorylation of tau at sites Ser (396&#8211;404) was reported to represent an early event in AD (Mondrag&#243;n-Rodr&#237;guez et al., <xref rid="B59" ref-type="bibr">2014</xref>). These suggest that GFKP-19 can reverse A&#946;<sub>25&#8722;35</sub> treatment induced up regulation of tau phosphorylation.</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>GFKP-19 decreases the phosphorylation of tau. (A)</bold> Fold change of tau phosphosites. The phosphorylation sites were S491, T523, S648, S688, S692, and S696 in mouse tau. The three experiment groups Control, A&#946;<sub>25&#8722;35</sub> and A&#946;<sub>25&#8722;35</sub>+GFKP-19 were represented with Con, Ab and GF. <bold>(B)</bold> Network analysis of kinases, phosphatases and tau (MAPT). The physical interaction was provided by SIGNOR. Red represents up regulation in ratio (A&#946;<sub>25&#8722;35</sub>+GFKP-19)/A&#946;<sub>25&#8722;35</sub> (GF vs. Ab), and green represents down regulation in GF vs. Ab. Interaction between MAPK14 and tau is shown with a red arrow.</p></caption><graphic xlink:href="fphys-07-00635-g0005"/></fig><p>To identify if GFKP-19 regulates the phosphorylation of tau through its kinase or phosphatases, interaction network was produced with physical interaction prediction through SIGNOR (Figure <xref ref-type="fig" rid="F5">5B</xref>). Protein phosphatase PP1 and PP2B are phosphatases of tau dephosphorylating tau at S199, S202, T205, T212, S214, S235, S262, S396, S404, and S409 and total phosphatase activity and the activity of PP2B toward tau were increased in AD brain (Liu et al., <xref rid="B51" ref-type="bibr">2005</xref>). Expression product of Ppp3ca is the catalytic subunit alpha isoform of PP2B. We found the phosphorylation of Ppp3ca at S462 was up regulated after treated with A&#946;<sub>25&#8722;35</sub> and was down regulated by GFKP-19. The phosphorylation level of PP1 detected in our study was unchanged. Tyrosine-protein kinase FYN has been reported to phosphorylate tau at T18, but the site was not detected in our study, and the phosphorylation of FYN at Y185 was slightly up regulated with GFKP-19 treatment (Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>), however, microtubule binding behavior of tau was not significantly altered by tyrosine phosphorylation of tau induced by FYN (Lee et al., <xref rid="B48" ref-type="bibr">2004</xref>). Microtubule-associated protein/microtubule affinity-regulating kinases (MARKs) have been proved to phosphorylate the KXGS motifs of tau's repeat domain which is crucial for microtubules interactions and aggregation (Drewes et al., <xref rid="B27" ref-type="bibr">1997</xref>; Biernat et al., <xref rid="B11" ref-type="bibr">2002</xref>). MARK2 can phosphorylates tau at S262 and the interaction between MARK2 and tau was reported to be enhanced in AD brain section (Gu et al., <xref rid="B34" ref-type="bibr">2013</xref>). MARK2 was also demonstrated to selectively phosphorylate eight serine residues in the repeat domain and C-terminal tail of tau and impact the structure and microtubule binding of tau (Schwalbe et al., <xref rid="B71" ref-type="bibr">2013</xref>) and significant increase tau phosphorylation level at S396/404 and decrease total tau levels (Cavallini et al., <xref rid="B14" ref-type="bibr">2013</xref>). We found that the phosphorylation of MARK2 at S499 and S533 were down regulated after treated with A&#946;<sub>25&#8722;35</sub> and reversed by GFKP-19, while these two sites were not previously discovered for MARK2. Mitogen-activated protein kinases (MAPK) are involved in tau hyperphosphorylation, and p38 MAPK has been reported to phosphorylate tau at S202, S205, S231, S356, and S404 (Hanger et al., <xref rid="B36" ref-type="bibr">2009</xref>). MAPK1 (ERK2) can reduce phosphorylation of tau at S396 (Cavallini et al., <xref rid="B14" ref-type="bibr">2013</xref>). Dual phosphorylation of MAPK1 at T183 and Y185 could be necessary for the activation of MAPK1 (Robbins et al., <xref rid="B67" ref-type="bibr">1993</xref>) and we found slightly increase in the phosphorylation level of MAPK1 at these two sites induced by GFKP-19 treatment (Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). MAPK14 (p38&#945;) had been reported to be a potential kinase of tau, and was related to a later onset of AD (V&#225;zquez-Higuera et al., <xref rid="B82" ref-type="bibr">2011</xref>). Phosphorylation of MAPK14 at T180 is necessary for its activation, while phosphorylation at both T180 and Y182 was more active than phosphorylation at T180 only (Zhang et al., <xref rid="B87" ref-type="bibr">2008</xref>). Although we did not quantify the phosphorylation of MAPK14 at Y182, we indeed detected the change of the phosphorylation of MAPK14 at T180, a very close phosphosite (Figure <xref ref-type="supplementary-material" rid="SM3">S6</xref> and Table <xref ref-type="supplementary-material" rid="SM3">S4</xref>). The phosphorylation level of MAPK14 at T180 was up regulated after A&#946;<sub>25&#8722;35</sub> treated, and down regulated with GFKP-19 treatment, suggesting that GFKP-19 may decrease tau phosphorylation through down regulating the phosphorylation level of MAPK14 at T180.</p></sec></sec><sec sec-type="conclusions" id="s4"><title>Conclusions</title><p>Firstly, it was authenticated in the current study that cytotoxicity induced by A&#946;<sub>25&#8722;35</sub> in neuro-2a cells could be successfully reversed by GFKP-19 treatment within 24 h. Thus, quantitative and comprehensive phosphoproteome analysis was carried out to explore the possible protective mechanism of GFKP-19 whereby treating neuro-2a cells with three different conditions (DMSO, 1 &#956;M A&#946;<sub>25&#8722;35</sub>, 1 &#956;M A&#946;<sub>25&#8722;35</sub> + 1 &#956;M GFKP-19).</p><p>Secondly, we screened the significantly changed phosphosites and corresponding phosphoproteins and found that 4 h is a good time point to inspect phosphorylation regulation. Gene Ontology (GO) processes, such as cytoskeleton protein binding, cell junction, and cell projection, were closely related to A&#946;<sub>25&#8722;35</sub> and GFKP-19 treatment. Next, particular motifs of phosphorylation sites were discovered, with which proteins were more possibly to be regulated by A&#946;<sub>25&#8722;35</sub> and GFKP-19, while experiments are further required.</p><p>Thirdly, we paid special attention to the proteins involved in the hypothesis of AD. Down-regulated phosphorylation of NO synthase NOS1 at S847 after A&#946;<sub>25&#8722;35</sub> treatment and its reverse with GFKP-19 treatment led to a possible hypothesis that GFKP-19 may protect neuro-2a cells from the cytotoxicity of A&#946;<sub>25&#8722;35</sub> via suppressing NO synthase NOS1 which in turn decrease oxidative damage and inflammation induced by NO. As a crucial protein involved in AD, tau was afterwards investigated for its relevance with GFKP-19. It seems the phosphorylation level of tau increase with A&#946;<sub>25&#8722;35</sub> treatment and phosphorylation treatment can switch it. Meanwhile, potential tau kinase MAPK14 showed phosphorylation change at T180, which was up regulated after treated with A&#946;<sub>25&#8722;35</sub>, and down regulated with the presence of GFKP-19. The preliminary assumption is that GFKP-19 protects neuro-2a cells from the damage of A&#946;<sub>25&#8722;35</sub> through decreasing tau phosphorylation which may be realized by down regulation of the phosphorylation level of MAPK14 at T180. We are currently working on generating alternative hypothesis using our data set.</p><p>In general, our three-channel SILAC strategy labeled three statuses, i.e., the control, the modeled disease, and the drug protected status, which is further combined with deep phosphoproteomic analysis enabled by extensive peptide-level fractionation and high-resolution mass spectrometry, providing a general framework to efficiently reveal the protective mechanisms of potential drugs. This strategy captures even subtle regulation events with a decent technical reproducibility and should be valuable for future similar studies.</p></sec><sec id="s5"><title>Author contributions</title><p>The manuscript was written by CY, YZ, YL, and HZ. CY, YL, and HZ designed the experiments. JZ, YL, and HZ supervised the experiments and revised the manuscript. CY performed the experiments with the assistance of XC and RX. CY and JG performed the statistical data analysis. All authors critically reviewed content and approved final version for publication.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>This research was supported by grants 21375138 and 31300681 from National Natural Science Foundation of China, by grant 2013ZX09507001 from the Ministry of Science and Technology of China, by &#8220;one hundred talent program&#8221; of Chinese Academy of Sciences, by the Strategic Priority Research Program of the Chinese Academy of Sciences, &#8220;Personalized Medicines-Molecular Signature-based Drug Discovery and Development&#8221; (No. XDA12030203), by the Innovation Project of Instrument and Equipment Function Development (Grant No. YZ201542 etc.) from the Bureau of Goods, Chinese Academy of Sciences and by grant JKLPRD201404 from the Open Project Program of Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine. The authors declare no conflict of interest. The mass spectrometry proteomics data have been deposited to be ProteomeXchange Consortium via the PRIDE (Vizca&#237;no et al., <xref rid="B83" ref-type="bibr">2016</xref>) partner repository with the dataset identifier PXD005312.</p></ack><sec sec-type="supplementary-material" id="s6"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fphys.2016.00635/full#supplementary-material">http://journal.frontiersin.org/article/10.3389/fphys.2016.00635/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Table1.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Table2.XLSX"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="DataSheet1.PDF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM4"><media xlink:href="DataSheet2.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraha</surname><given-names>A.</given-names></name><name><surname>Ghoshal</surname><given-names>N.</given-names></name><name><surname>Gamblin</surname><given-names>T. C.</given-names></name><name><surname>Cryns</surname><given-names>V.</given-names></name><name><surname>Berry</surname><given-names>R. W.</given-names></name><name><surname>Kuret</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2000</year>). <article-title>C-terminal inhibition of tau assembly <italic>in vitro</italic> and in Alzheimer's disease</article-title>. <source>J. Cell Sci.</source>
<volume>113</volume>(<issue>Pt 21</issue>), <fpage>3737</fpage>&#8211;<lpage>3745</lpage>. <?supplied-pmid 11034902?><pub-id pub-id-type="pmid">11034902</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aebersold</surname><given-names>R.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Mass spectrometry-based proteomics</article-title>. <source>Nature</source>
<volume>422</volume>, <fpage>198</fpage>&#8211;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1038/nature01511</pub-id><?supplied-pmid 12634793?><pub-id pub-id-type="pmid">12634793</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aebersold</surname><given-names>R.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Mass-spectrometric exploration of proteome structure and function</article-title>. <source>Nature</source>
<volume>537</volume>, <fpage>347</fpage>&#8211;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1038/nature19949</pub-id><?supplied-pmid 27629641?><pub-id pub-id-type="pmid">27629641</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amemori</surname><given-names>T.</given-names></name><name><surname>Jendelova</surname><given-names>P.</given-names></name><name><surname>Ruzicka</surname><given-names>J.</given-names></name><name><surname>Urdzikova</surname><given-names>L. M.</given-names></name><name><surname>Sykova</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Alzheimer's disease: mechanism and approach to cell therapy</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>16</volume>, <fpage>26417</fpage>&#8211;<lpage>26451</lpage>. <pub-id pub-id-type="doi">10.3390/ijms161125961</pub-id><?supplied-pmid 26556341?><pub-id pub-id-type="pmid">26556341</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>R.</given-names></name><name><surname>Gill</surname><given-names>K. D.</given-names></name><name><surname>Mahdi</surname><given-names>A. A.</given-names></name></person-group> (<year>2014</year>). <article-title>Therapeutics of Alzheimer's disease: past, present and future</article-title>. <source>Neuropharmacology</source>
<volume>76</volume>(<issue>Pt A</issue>), <fpage>27</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.07.004</pub-id><?supplied-pmid 23891641?><pub-id pub-id-type="pmid">23891641</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbor</surname><given-names>S. C.</given-names></name><name><surname>LaFontaine</surname><given-names>M.</given-names></name><name><surname>Cumbay</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores</article-title>. <source>Yale J. Biol. Med.</source>
<volume>89</volume>, <fpage>5</fpage>&#8211;<lpage>21</lpage>. <?supplied-pmid 27505013?><pub-id pub-id-type="pmid">27505013</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avila</surname><given-names>J.</given-names></name><name><surname>Lucas</surname><given-names>J. J.</given-names></name><name><surname>Perez</surname><given-names>M.</given-names></name><name><surname>Hernandez</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Role of tau protein in both physiological and pathological conditions</article-title>. <source>Physiol. Rev.</source>
<volume>84</volume>, <fpage>361</fpage>&#8211;<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00024.2003</pub-id><?supplied-pmid 15044677?><pub-id pub-id-type="pmid">15044677</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartus</surname><given-names>R. T.</given-names></name><name><surname>Dean</surname><given-names>R. L.</given-names><suffix>III</suffix></name><name><surname>Beer</surname><given-names>B.</given-names></name><name><surname>Lippa</surname><given-names>A. S.</given-names></name></person-group> (<year>1982</year>). <article-title>The cholinergic hypothesis of geriatric memory dysfunction</article-title>. <source>Science</source>
<volume>217</volume>, <fpage>408</fpage>&#8211;<lpage>414</lpage>. <?supplied-pmid 7046051?><pub-id pub-id-type="pmid">7046051</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batth</surname><given-names>T. S.</given-names></name><name><surname>Francavilla</surname><given-names>C.</given-names></name><name><surname>Olsen</surname><given-names>J. V.</given-names></name></person-group> (<year>2014</year>). <article-title>Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics</article-title>. <source>J. Proteome Res.</source>
<volume>13</volume>, <fpage>6176</fpage>&#8211;<lpage>6186</lpage>. <pub-id pub-id-type="doi">10.1021/pr500893m</pub-id><?supplied-pmid 25338131?><pub-id pub-id-type="pmid">25338131</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergamaschi</surname><given-names>D.</given-names></name><name><surname>Samuels</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>B.</given-names></name><name><surname>Duraisingham</surname><given-names>S.</given-names></name><name><surname>Crook</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group> (<year>2004</year>). <article-title>ASPP1 and ASPP2: common activators of p53 family members</article-title>. <source>Mol. Cell. Biol.</source>
<volume>24</volume>, <fpage>1341</fpage>&#8211;<lpage>1350</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.24.3.1341-1350.2004</pub-id><?supplied-pmid 14729977?><pub-id pub-id-type="pmid">14729977</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biernat</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>Y. Z.</given-names></name><name><surname>Timm</surname><given-names>T.</given-names></name><name><surname>Zheng-Fischh&#246;fer</surname><given-names>Q.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name><name><surname>Meijer</surname><given-names>L.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity</article-title>. <source>Mol. Biol. Cell</source>
<volume>13</volume>, <fpage>4013</fpage>&#8211;<lpage>4028</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.02-03-0046</pub-id><?supplied-pmid 12429843?><pub-id pub-id-type="pmid">12429843</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busciglio</surname><given-names>J.</given-names></name><name><surname>Lorenzo</surname><given-names>A.</given-names></name><name><surname>Yeh</surname><given-names>J.</given-names></name><name><surname>Yankner</surname><given-names>B. A.</given-names></name></person-group> (<year>1995</year>). <article-title>&#946;-amyloid fibrils induce tau phosphorylation and loss of microtubule binding</article-title>. <source>Neuron</source>
<volume>14</volume>, <fpage>879</fpage>&#8211;<lpage>888</lpage>. <?supplied-pmid 7718249?><pub-id pub-id-type="pmid">7718249</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caceres</surname><given-names>A.</given-names></name><name><surname>Kosik</surname><given-names>K. S.</given-names></name></person-group> (<year>1990</year>). <article-title>Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons</article-title>. <source>Nature</source>
<volume>343</volume>, <fpage>461</fpage>&#8211;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.1038/343461a0</pub-id><?supplied-pmid 2105469?><pub-id pub-id-type="pmid">2105469</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavallini</surname><given-names>A.</given-names></name><name><surname>Brewerton</surname><given-names>S.</given-names></name><name><surname>Bell</surname><given-names>A.</given-names></name><name><surname>Sargent</surname><given-names>S.</given-names></name><name><surname>Glover</surname><given-names>S.</given-names></name><name><surname>Hardy</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume>, <fpage>23331</fpage>&#8211;<lpage>23347</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.463984</pub-id><?supplied-pmid 23798682?><pub-id pub-id-type="pmid">23798682</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S. F.</given-names></name><name><surname>Zhang</surname><given-names>J. T.</given-names></name></person-group> (<year>2014</year>). <article-title>Recent advances in the study of (-)clausenamide: chemistry, biological activities and mechanism of action</article-title>. <source>Acta Pharm. Sin. B</source>
<volume>4</volume>, <fpage>417</fpage>&#8211;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2014.10.004</pub-id><?supplied-pmid 26579412?><pub-id pub-id-type="pmid">26579412</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Duan</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>The anti-dementia drug candidate, (-)-clausenamide, improves memory impairment through its multi-target effect</article-title>. <source>Pharmacol. Ther.</source>
<volume>162</volume>, <fpage>179</fpage>&#8211;<lpage>187</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2016.01.002</pub-id><?supplied-pmid 26812265?><pub-id pub-id-type="pmid">26812265</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clementi</surname><given-names>M. E.</given-names></name><name><surname>Marini</surname><given-names>S.</given-names></name><name><surname>Coletta</surname><given-names>M.</given-names></name><name><surname>Orsini</surname><given-names>F.</given-names></name><name><surname>Giardina</surname><given-names>B.</given-names></name><name><surname>Misiti</surname><given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>A&#946;(31-35) and A&#946;(25-35) fragments of amyloid beta-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35</article-title>. <source>FEBS Lett.</source>
<volume>579</volume>, <fpage>2913</fpage>&#8211;<lpage>2918</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2005.04.041</pub-id><?supplied-pmid 15890345?><pub-id pub-id-type="pmid">15890345</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>G. M.</given-names></name><name><surname>Frautschy</surname><given-names>S. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease</article-title>. <source>CNS Neurol. Disord. Drug Targets</source>
<volume>9</volume>, <fpage>140</fpage>&#8211;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.2174/187152710791011991</pub-id><?supplied-pmid 20205646?><pub-id pub-id-type="pmid">20205646</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title>. <source>Nat. Biotechnol.</source>
<volume>26</volume>, <fpage>1367</fpage>&#8211;<lpage>1372</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><?supplied-pmid 19029910?><pub-id pub-id-type="pmid">19029910</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>L. J.</given-names></name><name><surname>Stanley</surname><given-names>B. H.</given-names></name><name><surname>Melhem</surname><given-names>N. M.</given-names></name><name><surname>Oquendo</surname><given-names>M. A.</given-names></name><name><surname>Birmaher</surname><given-names>B.</given-names></name><name><surname>Burke</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Familial and individual correlates of nonsuicidal self-injury in the offspring of mood-disordered parents</article-title>. <source>J. Clin. Psychiatry</source>
<volume>73</volume>, <fpage>813</fpage>&#8211;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.4088/JCP.11m07196</pub-id><?supplied-pmid 22795206?><pub-id pub-id-type="pmid">22795206</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Monte</surname><given-names>S. M.</given-names></name><name><surname>Wands</surname><given-names>J. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>9</volume>, <fpage>167</fpage>&#8211;<lpage>181</lpage>. <?supplied-pmid 16873964?><pub-id pub-id-type="pmid">16873964</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dengjel</surname><given-names>J.</given-names></name><name><surname>Akimov</surname><given-names>V.</given-names></name><name><surname>Olsen</surname><given-names>J. V.</given-names></name><name><surname>Bunkenborg</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name><name><surname>Blagoev</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Quantitative proteomic assessment of very early cellular signaling events</article-title>. <source>Nat. Biotechnol.</source>
<volume>25</volume>, <fpage>566</fpage>&#8211;<lpage>568</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1301</pub-id><?supplied-pmid 17450129?><pub-id pub-id-type="pmid">17450129</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dephoure</surname><given-names>N.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Vill&#233;n</surname><given-names>J.</given-names></name><name><surname>Beausoleil</surname><given-names>S. A.</given-names></name><name><surname>Bakalarski</surname><given-names>C. E.</given-names></name><name><surname>Elledge</surname><given-names>S. J.</given-names></name><etal/></person-group>. (<year>2008</year>). <article-title>A quantitative atlas of mitotic phosphorylation</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>105</volume>, <fpage>10762</fpage>&#8211;<lpage>10767</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0805139105</pub-id><?supplied-pmid 18669648?><pub-id pub-id-type="pmid">18669648</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Strooper</surname><given-names>B.</given-names></name></person-group> (<year>2010</year>). <article-title>Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process</article-title>. <source>Physiol. Rev.</source>
<volume>90</volume>, <fpage>465</fpage>&#8211;<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00023.2009</pub-id><?supplied-pmid 20393191?><pub-id pub-id-type="pmid">20393191</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dillen</surname><given-names>L.</given-names></name><name><surname>Cools</surname><given-names>W.</given-names></name><name><surname>Vereyken</surname><given-names>L.</given-names></name><name><surname>Timmerman</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species</article-title>. <source>Bioanalysis</source>
<volume>3</volume>, <fpage>45</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.4155/bio.10.163</pub-id><?supplied-pmid 21175366?><pub-id pub-id-type="pmid">21175366</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drachman</surname><given-names>D. A.</given-names></name><name><surname>Leavitt</surname><given-names>J.</given-names></name></person-group> (<year>1974</year>). <article-title>Human memory and the cholinergic system. A relationship to aging?</article-title>
<source>Arch. Neurol.</source>
<volume>30</volume>, <fpage>113</fpage>&#8211;<lpage>121</lpage>. <?supplied-pmid 4359364?><pub-id pub-id-type="pmid">4359364</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drewes</surname><given-names>G.</given-names></name><name><surname>Ebneth</surname><given-names>A.</given-names></name><name><surname>Preuss</surname><given-names>U.</given-names></name><name><surname>Mandelkow</surname><given-names>E. M.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group> (<year>1997</year>). <article-title>MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption</article-title>. <source>Cell</source>
<volume>89</volume>, <fpage>297</fpage>&#8211;<lpage>308</lpage>. <?supplied-pmid 9108484?><pub-id pub-id-type="pmid">9108484</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliasson</surname><given-names>M. J.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Ferrante</surname><given-names>R. J.</given-names></name><name><surname>Sasamata</surname><given-names>M.</given-names></name><name><surname>Molliver</surname><given-names>M. E.</given-names></name><name><surname>Snyder</surname><given-names>S. H.</given-names></name><etal/></person-group>. (<year>1999</year>). <article-title>Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage</article-title>. <source>J. Neurosci.</source>
<volume>19</volume>, <fpage>5910</fpage>&#8211;<lpage>5918</lpage>. <?supplied-pmid 10407030?><pub-id pub-id-type="pmid">10407030</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>D. B.</given-names></name><name><surname>Rank</surname><given-names>K. B.</given-names></name><name><surname>Bhattacharya</surname><given-names>K.</given-names></name><name><surname>Thomsen</surname><given-names>D. R.</given-names></name><name><surname>Gurney</surname><given-names>M. E.</given-names></name><name><surname>Sharma</surname><given-names>S. K.</given-names></name></person-group> (<year>2000</year>). <article-title>Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly</article-title>. <source>J. Biol. Chem.</source>
<volume>275</volume>, <fpage>24977</fpage>&#8211;<lpage>24983</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M000808200</pub-id><?supplied-pmid 10818091?><pub-id pub-id-type="pmid">10818091</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>J. M.</given-names></name><name><surname>Carmines</surname><given-names>P. K.</given-names></name><name><surname>Pollock</surname><given-names>J. S.</given-names></name></person-group> (<year>2009</year>). <article-title>PP2B-dependent NO production in the medullary thick ascending limb during diabetes</article-title>. <source>Am. J. Physiol. Renal Physiol.</source>
<volume>297</volume>, <fpage>F471</fpage>&#8211;<lpage>F480</lpage>. <pub-id pub-id-type="doi">10.1152/ajprenal.90760.2008</pub-id><?supplied-pmid 19458119?><pub-id pub-id-type="pmid">19458119</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galimberti</surname><given-names>D.</given-names></name><name><surname>Scarpini</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Inflammation and oxidative damage in Alzheimer's disease: friend or foe?</article-title>
<source>Front. Biosci. (Schol. Ed).</source>
<volume>3</volume>, <fpage>252</fpage>&#8211;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.2741/s149</pub-id><?supplied-pmid 21196374?><pub-id pub-id-type="pmid">21196374</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>M. L.</given-names></name><name><surname>Cleveland</surname><given-names>D. W.</given-names></name></person-group> (<year>2001</year>). <article-title>Going new places using an old MAP: tau, microtubules and human neurodegenerative disease</article-title>. <source>Curr. Opin. Cell Biol.</source>
<volume>13</volume>, <fpage>41</fpage>&#8211;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/S0955-0674(00)00172-1</pub-id><?supplied-pmid 11163132?><pub-id pub-id-type="pmid">11163132</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godin-Heymann</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Slee</surname><given-names>E.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group> (<year>2013</year>). <article-title>Phosphorylation of ASPP2 by RAS/MAPK pathway is critical for its full pro-apoptotic function</article-title>. <source>PLoS ONE</source>
<volume>8</volume>:<fpage>e82022</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0082022</pub-id><?supplied-pmid 24312625?><pub-id pub-id-type="pmid">24312625</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>G. J.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Lund</surname><given-names>H.</given-names></name><name><surname>Sunnemark</surname><given-names>D.</given-names></name><name><surname>Kvist</surname><given-names>A. J.</given-names></name><name><surname>Milner</surname><given-names>R.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Elevated MARK2-dependent phosphorylation of Tau in Alzheimer's disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>33</volume>, <fpage>699</fpage>&#8211;<lpage>713</lpage>. <pub-id pub-id-type="doi">10.3233/jad-2012-121357</pub-id><?supplied-pmid 23001711?><pub-id pub-id-type="pmid">23001711</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haase</surname><given-names>C.</given-names></name><name><surname>Stieler</surname><given-names>J. T.</given-names></name><name><surname>Arendt</surname><given-names>T.</given-names></name><name><surname>Holzer</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Pseudophosphorylation of tau protein alters its ability for self-aggregation</article-title>. <source>J. Neurochem.</source>
<volume>88</volume>, <fpage>1509</fpage>&#8211;<lpage>1520</lpage>. <pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.02287.x</pub-id><?supplied-pmid 15009652?><pub-id pub-id-type="pmid">15009652</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanger</surname><given-names>D. P.</given-names></name><name><surname>Anderton</surname><given-names>B. H.</given-names></name><name><surname>Noble</surname><given-names>W.</given-names></name></person-group> (<year>2009</year>). <article-title>Tau phosphorylation: the therapeutic challenge for neurodegenerative disease</article-title>. <source>Trends Mol. Med.</source>
<volume>15</volume>, <fpage>112</fpage>&#8211;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2009.01.003</pub-id><?supplied-pmid 19246243?><pub-id pub-id-type="pmid">19246243</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J. A.</given-names></name><name><surname>Higgins</surname><given-names>G. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Alzheimer's disease: the amyloid cascade hypothesis</article-title>. <source>Science</source>
<volume>256</volume>, <fpage>184</fpage>&#8211;<lpage>185</lpage>. <?supplied-pmid 1566067?><pub-id pub-id-type="pmid">1566067</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hejazi</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>J. W.</given-names></name><name><surname>Cheng</surname><given-names>D.</given-names></name><name><surname>Proschogo</surname><given-names>N.</given-names></name><name><surname>Ebrahimi</surname><given-names>D.</given-names></name><name><surname>Garner</surname><given-names>B.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains</article-title>. <source>Biochem. J.</source>
<volume>438</volume>, <fpage>165</fpage>&#8211;<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1042/bj20110566</pub-id><?supplied-pmid 21639855?><pub-id pub-id-type="pmid">21639855</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname><given-names>M.</given-names></name><name><surname>Bonaldi</surname><given-names>T.</given-names></name><name><surname>Gnad</surname><given-names>F.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Systems-wide analysis of a phosphatase knock-down by quantitative proteomics and phosphoproteomics</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>8</volume>, <fpage>1908</fpage>&#8211;<lpage>1920</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M800559-MCP200</pub-id><?supplied-pmid 19429919?><pub-id pub-id-type="pmid">19429919</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtzman</surname><given-names>D. M.</given-names></name><name><surname>Morris</surname><given-names>J. C.</given-names></name><name><surname>Goate</surname><given-names>A. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Alzheimer's disease: the challenge of the second century</article-title>. <source>Sci. Transl. Med.</source>
<volume>3</volume>:<fpage>77s</fpage>r71. <pub-id pub-id-type="doi">10.1126/scitranslmed.3002369</pub-id><?supplied-pmid 21471435?><pub-id pub-id-type="pmid">21471435</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J. F.</given-names></name><name><surname>Chu</surname><given-names>S. F.</given-names></name><name><surname>Ning</surname><given-names>N.</given-names></name><name><surname>Yuan</surname><given-names>Y. H.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>N. H.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Protective effect of (-)clausenamide against A&#946;-induced neurotoxicity in differentiated PC12 cells</article-title>. <source>Neurosci. Lett.</source>
<volume>483</volume>, <fpage>78</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2010.07.067</pub-id><?supplied-pmid 20674676?><pub-id pub-id-type="pmid">20674676</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imtiaz</surname><given-names>B.</given-names></name><name><surname>Tolppanen</surname><given-names>A. M.</given-names></name><name><surname>Kivipelto</surname><given-names>M.</given-names></name><name><surname>Soininen</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>Future directions in Alzheimer's disease from risk factors to prevention</article-title>. <source>Biochem. Pharmacol.</source>
<volume>88</volume>, <fpage>661</fpage>&#8211;<lpage>670</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2014.01.003</pub-id><?supplied-pmid 24418410?><pub-id pub-id-type="pmid">24418410</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khlistunova</surname><given-names>I.</given-names></name><name><surname>Pickhardt</surname><given-names>M.</given-names></name><name><surname>Biernat</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Mandelkow</surname><given-names>E. M.</given-names></name><name><surname>Mandelkow</surname><given-names>E.</given-names></name></person-group> (<year>2007</year>). <article-title>Inhibition of tau aggregation in cell models of tauopathy</article-title>. <source>Curr. Alzheimer Res.</source>
<volume>4</volume>, <fpage>544</fpage>&#8211;<lpage>546</lpage>. <pub-id pub-id-type="doi">10.2174/156720507783018307</pub-id><?supplied-pmid 18220518?><pub-id pub-id-type="pmid">18220518</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koliaki</surname><given-names>C. C.</given-names></name><name><surname>Messini</surname><given-names>C.</given-names></name><name><surname>Tsolaki</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study</article-title>. <source>CNS Neurosci. Ther.</source>
<volume>18</volume>, <fpage>302</fpage>&#8211;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00244.x</pub-id><?supplied-pmid 22070796?><pub-id pub-id-type="pmid">22070796</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulak</surname><given-names>N. A.</given-names></name><name><surname>Pichler</surname><given-names>G.</given-names></name><name><surname>Paron</surname><given-names>I.</given-names></name><name><surname>Nagaraj</surname><given-names>N.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells</article-title>. <source>Nat. Methods</source>
<volume>11</volume>, <fpage>319</fpage>&#8211;<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2834</pub-id><?supplied-pmid 24487582?><pub-id pub-id-type="pmid">24487582</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasagna-Reeves</surname><given-names>C. A.</given-names></name><name><surname>Castillo-Carranza</surname><given-names>D. L.</given-names></name><name><surname>Sengupta</surname><given-names>U.</given-names></name><name><surname>Sarmiento</surname><given-names>J.</given-names></name><name><surname>Troncoso</surname><given-names>J.</given-names></name><name><surname>Jackson</surname><given-names>G. R.</given-names></name><etal/></person-group>. (<year>2012</year>). <article-title>Identification of oligomers at early stages of tau aggregation in Alzheimer's disease</article-title>. <source>FASEB J.</source>
<volume>26</volume>, <fpage>1946</fpage>&#8211;<lpage>1959</lpage>. <pub-id pub-id-type="doi">10.1096/fj.11-199851</pub-id><?supplied-pmid 22253473?><pub-id pub-id-type="pmid">22253473</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>A.</given-names></name><name><surname>Gauthier</surname><given-names>S.</given-names></name><name><surname>Quirion</surname><given-names>R.</given-names></name></person-group> (<year>2001</year>). <article-title>Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type</article-title>. <source>Brain Res. Brain Res. Rev.</source>
<volume>35</volume>, <fpage>73</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1016/S0165-0173(00)00051-5</pub-id><?supplied-pmid 11245887?><pub-id pub-id-type="pmid">11245887</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G.</given-names></name><name><surname>Thangavel</surname><given-names>R.</given-names></name><name><surname>Sharma</surname><given-names>V. M.</given-names></name><name><surname>Litersky</surname><given-names>J. M.</given-names></name><name><surname>Bhaskar</surname><given-names>K.</given-names></name><name><surname>Fang</surname><given-names>S. M.</given-names></name><etal/></person-group>. (<year>2004</year>). <article-title>Phosphorylation of tau by fyn: implications for Alzheimer's disease</article-title>. <source>J. Neurosci.</source>
<volume>24</volume>, <fpage>2304</fpage>&#8211;<lpage>2312</lpage>. <pub-id pub-id-type="doi">10.1523/jneurosci.4162-03.2004</pub-id><?supplied-pmid 14999081?><pub-id pub-id-type="pmid">14999081</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. P.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Casadesus</surname><given-names>G.</given-names></name><name><surname>Castellani</surname><given-names>R. J.</given-names></name><name><surname>Nunomura</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>Antioxidant approaches for the treatment of Alzheimer's disease</article-title>. <source>Expert Rev. Neurother.</source>
<volume>10</volume>, <fpage>1201</fpage>&#8211;<lpage>1208</lpage>. <pub-id pub-id-type="doi">10.1586/ern.10.74</pub-id><?supplied-pmid 20586698?><pub-id pub-id-type="pmid">20586698</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindwall</surname><given-names>G.</given-names></name><name><surname>Cole</surname><given-names>R. D.</given-names></name></person-group> (<year>1984</year>). <article-title>Phosphorylation affects the ability of tau protein to promote microtubule assembly</article-title>. <source>J. Biol. Chem.</source>
<volume>259</volume>, <fpage>5301</fpage>&#8211;<lpage>5305</lpage>. <?supplied-pmid 6425287?><pub-id pub-id-type="pmid">6425287</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Grundke-Iqbal</surname><given-names>I.</given-names></name><name><surname>Iqbal</surname><given-names>K.</given-names></name><name><surname>Gong</surname><given-names>C. X.</given-names></name></person-group> (<year>2005</year>). <article-title>Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation</article-title>. <source>Eur. J. Neurosci.</source>
<volume>22</volume>, <fpage>1942</fpage>&#8211;<lpage>1950</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04391.x</pub-id><?supplied-pmid 16262633?><pub-id pub-id-type="pmid">16262633</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>H. B.</given-names></name><name><surname>Xia</surname><given-names>Y. Y.</given-names></name><name><surname>Shu</surname><given-names>X. J.</given-names></name><name><surname>Liu</surname><given-names>Z. C.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>X. H.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>111</volume>, <fpage>16586</fpage>&#8211;<lpage>16591</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1417548111</pub-id><?supplied-pmid 25378699?><pub-id pub-id-type="pmid">25378699</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynn</surname><given-names>B. C.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Markesbery</surname><given-names>W. R.</given-names></name><name><surname>Lovell</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Quantitative changes in the mitochondrial proteome from subjects with mild cognitive impairment, early stage, and late stage Alzheimer's disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>19</volume>, <fpage>325</fpage>&#8211;<lpage>339</lpage>. <pub-id pub-id-type="doi">10.3233/jad-2010-1254</pub-id><?supplied-pmid 20061648?><pub-id pub-id-type="pmid">20061648</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsden</surname><given-names>I. T.</given-names></name><name><surname>Minamide</surname><given-names>L. S.</given-names></name><name><surname>Bamburg</surname><given-names>J. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Amyloid-&#946;-induced amyloid-&#946; secretion: a possible feed-forward mechanism in Alzheimer's Disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>24</volume>, <fpage>681</fpage>&#8211;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.3233/jad-2011-101899</pub-id><?supplied-pmid 21297255?><pub-id pub-id-type="pmid">21297255</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L.</given-names></name><name><surname>Latypova</surname><given-names>X.</given-names></name><name><surname>Wilson</surname><given-names>C. M.</given-names></name><name><surname>Magnaudeix</surname><given-names>A.</given-names></name><name><surname>Perrin</surname><given-names>M. L.</given-names></name><name><surname>Yardin</surname><given-names>C.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Tau protein kinases: involvement in Alzheimer's disease</article-title>. <source>Ageing Res. Rev.</source>
<volume>12</volume>, <fpage>289</fpage>&#8211;<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2012.06.003</pub-id><?supplied-pmid 22742992?><pub-id pub-id-type="pmid">22742992</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurage</surname><given-names>C. A.</given-names></name><name><surname>Sergeant</surname><given-names>N.</given-names></name><name><surname>Ruchoux</surname><given-names>M. M.</given-names></name><name><surname>Hauw</surname><given-names>J. J.</given-names></name><name><surname>Delacourte</surname><given-names>A.</given-names></name></person-group> (<year>2003</year>). <article-title>Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology</article-title>. <source>Acta Neuropathol.</source>
<volume>105</volume>, <fpage>89</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s00401-002-0608-7</pub-id><?supplied-pmid 12536218?><pub-id pub-id-type="pmid">12536218</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertins</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Mani</surname><given-names>D. R.</given-names></name><name><surname>Petyuk</surname><given-names>V. A.</given-names></name><name><surname>Gillette</surname><given-names>M. A.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>13</volume>, <fpage>1690</fpage>&#8211;<lpage>1704</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M113.036392</pub-id><?supplied-pmid 24719451?><pub-id pub-id-type="pmid">24719451</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalski</surname><given-names>A.</given-names></name><name><surname>Damoc</surname><given-names>E.</given-names></name><name><surname>Hauschild</surname><given-names>J. P.</given-names></name><name><surname>Lange</surname><given-names>O.</given-names></name><name><surname>Wieghaus</surname><given-names>A.</given-names></name><name><surname>Makarov</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>10</volume>:<fpage>M111</fpage>.011015. <pub-id pub-id-type="doi">10.1074/mcp.M111.011015</pub-id><?supplied-pmid 21642640?><pub-id pub-id-type="pmid">21642640</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mondrag&#243;n-Rodr&#237;guez</surname><given-names>S.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Luna-Munoz</surname><given-names>J.</given-names></name><name><surname>Acevedo-Aquino</surname><given-names>M. C.</given-names></name><name><surname>Williams</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer's disease and Down syndrome</article-title>. <source>Neuropathol. Appl. Neurobiol.</source>
<volume>40</volume>, <fpage>121</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1111/nan.12084</pub-id><?supplied-pmid 24033439?><pub-id pub-id-type="pmid">24033439</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T.</given-names></name></person-group> (<year>1983</year>). <article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title>. <source>J. Immunol. Methods</source>
<volume>65</volume>, <fpage>55</fpage>&#8211;<lpage>63</lpage>. <?supplied-pmid 6606682?><pub-id pub-id-type="pmid">6606682</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>S. E.</given-names></name><name><surname>Blagoev</surname><given-names>B.</given-names></name><name><surname>Kratchmarova</surname><given-names>I.</given-names></name><name><surname>Kristensen</surname><given-names>D. B.</given-names></name><name><surname>Steen</surname><given-names>H.</given-names></name><name><surname>Pandey</surname><given-names>A.</given-names></name><etal/></person-group>. (<year>2002</year>). <article-title>Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>1</volume>, <fpage>376</fpage>&#8211;<lpage>386</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M200025-MCP200</pub-id><?supplied-pmid 12118079?><pub-id pub-id-type="pmid">12118079</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>S. E.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC)</article-title>. <source>Nat. Protoc.</source>
<volume>1</volume>, <fpage>2650</fpage>&#8211;<lpage>2660</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2006.427</pub-id><?supplied-pmid 17406521?><pub-id pub-id-type="pmid">17406521</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Olsen</surname><given-names>J. V.</given-names></name><name><surname>Daub</surname><given-names>H.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>8</volume>, <fpage>2796</fpage>&#8211;<lpage>2808</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M900285-MCP200</pub-id><?supplied-pmid 19651622?><pub-id pub-id-type="pmid">19651622</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perfetto</surname><given-names>L.</given-names></name><name><surname>Briganti</surname><given-names>L.</given-names></name><name><surname>Calderone</surname><given-names>A.</given-names></name><name><surname>Perpetuini</surname><given-names>A. C.</given-names></name><name><surname>Iannuccelli</surname><given-names>M.</given-names></name><name><surname>Langone</surname><given-names>F.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>SIGNOR: a database of causal relationships between biological entities</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>D548</fpage>&#8211;<lpage>D554</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1048</pub-id><?supplied-pmid 26467481?><pub-id pub-id-type="pmid">26467481</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pickhardt</surname><given-names>M.</given-names></name><name><surname>Biernat</surname><given-names>J.</given-names></name><name><surname>Khlistunova</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>Y. P.</given-names></name><name><surname>Gazova</surname><given-names>Z.</given-names></name><name><surname>Mandelkow</surname><given-names>E. M.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy</article-title>. <source>Curr. Alzheimer Res.</source>
<volume>4</volume>, <fpage>397</fpage>&#8211;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.2174/156720507781788765</pub-id><?supplied-pmid 17908042?><pub-id pub-id-type="pmid">17908042</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pike</surname><given-names>C. J.</given-names></name><name><surname>Walencewicz-Wasserman</surname><given-names>A. J.</given-names></name><name><surname>Kosmoski</surname><given-names>J.</given-names></name><name><surname>Cribbs</surname><given-names>D. H.</given-names></name><name><surname>Glabe</surname><given-names>C. G.</given-names></name><name><surname>Cotman</surname><given-names>C. W.</given-names></name></person-group> (<year>1995</year>). <article-title>Structure-activity analyses of &#946;-amyloid peptides: contributions of the &#946;25-35 region to aggregation and neurotoxicity</article-title>. <source>J. Neurochem.</source>
<volume>64</volume>, <fpage>253</fpage>&#8211;<lpage>265</lpage>. <?supplied-pmid 7798921?><pub-id pub-id-type="pmid">7798921</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>D. J.</given-names></name><name><surname>Zhen</surname><given-names>E.</given-names></name><name><surname>Owaki</surname><given-names>H.</given-names></name><name><surname>Vanderbilt</surname><given-names>C. A.</given-names></name><name><surname>Ebert</surname><given-names>D.</given-names></name><name><surname>Geppert</surname><given-names>T. D.</given-names></name><etal/></person-group>. (<year>1993</year>). <article-title>Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 <italic>in vitro</italic></article-title>. <source>J. Biol. Chem.</source>
<volume>268</volume>, <fpage>5097</fpage>&#8211;<lpage>5106</lpage>. <?supplied-pmid 8444886?><pub-id pub-id-type="pmid">8444886</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roux</surname><given-names>P. P.</given-names></name><name><surname>Thibault</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>The coming of age of phosphoproteomics&#8211;from large data sets to inference of protein functions</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>12</volume>, <fpage>3453</fpage>&#8211;<lpage>3464</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.R113.032862</pub-id><?supplied-pmid 24037665?><pub-id pub-id-type="pmid">24037665</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samuels-Lev</surname><given-names>Y.</given-names></name><name><surname>O'Connor</surname><given-names>D. J.</given-names></name><name><surname>Bergamaschi</surname><given-names>D.</given-names></name><name><surname>Trigiante</surname><given-names>G.</given-names></name><name><surname>Hsieh</surname><given-names>J. K.</given-names></name><name><surname>Zhong</surname><given-names>S.</given-names></name><etal/></person-group>. (<year>2001</year>). <article-title>ASPP proteins specifically stimulate the apoptotic function of p53</article-title>. <source>Mol. Cell</source>
<volume>8</volume>, <fpage>781</fpage>&#8211;<lpage>794</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(01)00367-7</pub-id><?supplied-pmid 11684014?><pub-id pub-id-type="pmid">11684014</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheltema</surname><given-names>R. A.</given-names></name><name><surname>Hauschild</surname><given-names>J. P.</given-names></name><name><surname>Lange</surname><given-names>O.</given-names></name><name><surname>Hornburg</surname><given-names>D.</given-names></name><name><surname>Denisov</surname><given-names>E.</given-names></name><name><surname>Damoc</surname><given-names>E.</given-names></name><etal/></person-group>. (<year>2014</year>). <article-title>The Q Exactive HF, a Benchtop mass spectrometer with a pre-filter, high-performance quadrupole and an ultra-high-field Orbitrap analyzer</article-title>. <source>Mol. Cell. Proteomics</source>
<volume>13</volume>, <fpage>3698</fpage>&#8211;<lpage>3708</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M114.043489</pub-id><?supplied-pmid 25360005?><pub-id pub-id-type="pmid">25360005</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwalbe</surname><given-names>M.</given-names></name><name><surname>Biernat</surname><given-names>J.</given-names></name><name><surname>Bibow</surname><given-names>S.</given-names></name><name><surname>Ozenne</surname><given-names>V.</given-names></name><name><surname>Jensen</surname><given-names>M. R.</given-names></name><name><surname>Kadavath</surname><given-names>H.</given-names></name><etal/></person-group>. (<year>2013</year>). <article-title>Phosphorylation of human Tau protein by microtubule affinity-regulating kinase 2</article-title>. <source>Biochemistry</source>
<volume>52</volume>, <fpage>9068</fpage>&#8211;<lpage>9079</lpage>. <pub-id pub-id-type="doi">10.1021/bi401266n</pub-id><?supplied-pmid 24251416?><pub-id pub-id-type="pmid">24251416</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>D.</given-names></name><name><surname>Gygi</surname><given-names>S. P.</given-names></name></person-group> (<year>2005</year>). <article-title>An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets</article-title>. <source>Nat. Biotechnol.</source>
<volume>23</volume>, <fpage>1391</fpage>&#8211;<lpage>1398</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1146</pub-id><?supplied-pmid 16273072?><pub-id pub-id-type="pmid">16273072</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selenica</surname><given-names>M. L.</given-names></name><name><surname>Jensen</surname><given-names>H. S.</given-names></name><name><surname>Larsen</surname><given-names>A. K.</given-names></name><name><surname>Pedersen</surname><given-names>M. L.</given-names></name><name><surname>Helboe</surname><given-names>L.</given-names></name><name><surname>Leist</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2007</year>). <article-title>Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation</article-title>. <source>Br. J. Pharmacol.</source>
<volume>152</volume>, <fpage>959</fpage>&#8211;<lpage>979</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707471</pub-id><?supplied-pmid 17906685?><pub-id pub-id-type="pmid">17906685</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih</surname><given-names>P. H.</given-names></name><name><surname>Wu</surname><given-names>C. H.</given-names></name><name><surname>Yeh</surname><given-names>C. T.</given-names></name><name><surname>Yen</surname><given-names>G. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Protective effects of anthocyanins against amyloid &#946;-peptide-induced damage in neuro-2A cells</article-title>. <source>J. Agric. Food Chem.</source>
<volume>59</volume>, <fpage>1683</fpage>&#8211;<lpage>1689</lpage>. <pub-id pub-id-type="doi">10.1021/jf103822h</pub-id><?supplied-pmid 21302893?><pub-id pub-id-type="pmid">21302893</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>R. H.</given-names></name></person-group> (<year>2002</year>). <article-title>Mitochondrial DNA&#8211;related mitochondrial dysfunction in neurodegenerative diseases</article-title>. <source>Arch. Pathol. Lab. Med.</source>
<volume>126</volume>, <fpage>271</fpage>&#8211;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1043/0003-9985(2002)126&lt;0271:mdrmdi&gt;2.0.co;2</pub-id><?supplied-pmid 11860299?><pub-id pub-id-type="pmid">11860299</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>R. H.</given-names></name><name><surname>Khan</surname><given-names>S. M.</given-names></name></person-group> (<year>2004</year>). <article-title>A &#8220;mitochondrial cascade hypothesis&#8221; for sporadic Alzheimer's disease</article-title>. <source>Med. Hypotheses</source>
<volume>63</volume>, <fpage>8</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2003.12.045</pub-id><?supplied-pmid 15193340?><pub-id pub-id-type="pmid">15193340</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thingholm</surname><given-names>T. E.</given-names></name><name><surname>J&#248;rgensen</surname><given-names>T. J.</given-names></name><name><surname>Jensen</surname><given-names>O. N.</given-names></name><name><surname>Larsen</surname><given-names>M. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Highly selective enrichment of phosphorylated peptides using titanium dioxide</article-title>. <source>Nat. Protoc.</source>
<volume>1</volume>, <fpage>1929</fpage>&#8211;<lpage>1935</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2006.185</pub-id><?supplied-pmid 17487178?><pub-id pub-id-type="pmid">17487178</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>C.</given-names></name><name><surname>Bright</surname><given-names>N. J.</given-names></name><name><surname>Sastre</surname><given-names>M.</given-names></name><name><surname>Muckett</surname><given-names>P. J.</given-names></name><name><surname>Carling</surname><given-names>D.</given-names></name></person-group> (<year>2011</year>). <article-title>AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid &#946;-peptide exposure</article-title>. <source>Biochem. J.</source>
<volume>434</volume>, <fpage>503</fpage>&#8211;<lpage>512</lpage>. <pub-id pub-id-type="doi">10.1042/bj20101485</pub-id><?supplied-pmid 21204788?><pub-id pub-id-type="pmid">21204788</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S.</given-names></name><name><surname>Temu</surname><given-names>T.</given-names></name><name><surname>Sinitcyn</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>). <article-title>The Perseus computational platform for comprehensive analysis of (prote)omics data</article-title>. <source>Nat. Methods</source>
<volume>13</volume>, <fpage>731</fpage>&#8211;<lpage>740</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3901</pub-id><?supplied-pmid 27348712?><pub-id pub-id-type="pmid">27348712</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulukaya</surname><given-names>E.</given-names></name><name><surname>Colakogullari</surname><given-names>M.</given-names></name><name><surname>Wood</surname><given-names>E. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay</article-title>. <source>Chemotherapy</source>
<volume>50</volume>, <fpage>43</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1159/000077285</pub-id><?supplied-pmid 15084806?><pub-id pub-id-type="pmid">15084806</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Cauwenberghe</surname><given-names>C.</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>The genetic landscape of Alzheimer disease: clinical implications and Perspectives</article-title>. <source>Genet. Med.</source>
<volume>18</volume>, <fpage>421</fpage>&#8211;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2015.117</pub-id><?supplied-pmid 26312828?><pub-id pub-id-type="pmid">26312828</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#225;zquez-Higuera</surname><given-names>J. L.</given-names></name><name><surname>Mateo</surname><given-names>I.</given-names></name><name><surname>S&#225;nchez-Juan</surname><given-names>P.</given-names></name><name><surname>Rodr&#237;guez-Rodr&#237;guez</surname><given-names>E.</given-names></name><name><surname>Pozueta</surname><given-names>A.</given-names></name><name><surname>Calero</surname><given-names>M.</given-names></name><etal/></person-group>. (<year>2011</year>). <article-title>Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease</article-title>. <source>J. Alzheimers. Dis.</source>
<volume>27</volume>, <fpage>291</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2011-110794</pub-id><?supplied-pmid 21811019?><pub-id pub-id-type="pmid">21811019</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizca&#237;no</surname><given-names>J. A.</given-names></name><name><surname>Csordas</surname><given-names>A.</given-names></name><name><surname>del-Toro</surname><given-names>N.</given-names></name><name><surname>Dianes</surname><given-names>J. A.</given-names></name><name><surname>Griss</surname><given-names>J.</given-names></name><name><surname>Lavidas</surname><given-names>I.</given-names></name><etal/></person-group>. (<year>2016</year>). <article-title>2016 update of the PRIDE database and its related tools</article-title>. <source>Nucleic Acids Res.</source>
<volume>44</volume>, <fpage>D447</fpage>&#8211;<lpage>D456</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkv1145</pub-id><?supplied-pmid 27683222?><pub-id pub-id-type="pmid">26527722</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walther</surname><given-names>D. M.</given-names></name><name><surname>Kasturi</surname><given-names>P.</given-names></name><name><surname>Zheng</surname><given-names>M.</given-names></name><name><surname>Pinkert</surname><given-names>S.</given-names></name><name><surname>Vecchi</surname><given-names>G.</given-names></name><name><surname>Ciryam</surname><given-names>P.</given-names></name><etal/></person-group>. (<year>2015</year>). <article-title>Widespread proteome remodeling and aggregation in aging C. elegans</article-title>. <source>Cell</source>
<volume>161</volume>, <fpage>919</fpage>&#8211;<lpage>932</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.03.032</pub-id><?supplied-pmid 25957690?><pub-id pub-id-type="pmid">25957690</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintz</surname><given-names>G.</given-names></name><name><surname>Olsen</surname><given-names>J. V.</given-names></name><name><surname>Fr&#252;hauf</surname><given-names>K.</given-names></name><name><surname>Niedzielska</surname><given-names>M.</given-names></name><name><surname>Amit</surname><given-names>I.</given-names></name><name><surname>Jantsch</surname><given-names>J.</given-names></name><etal/></person-group>. (<year>2010</year>). <article-title>The phosphoproteome of toll-like receptor-activated macrophages</article-title>. <source>Mol. Syst. Biol.</source>
<volume>6</volume>, <fpage>371</fpage>. <pub-id pub-id-type="doi">10.1038/msb.2010.29</pub-id><?supplied-pmid 20531401?><pub-id pub-id-type="pmid">20531401</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wisniewski</surname><given-names>J. R.</given-names></name><name><surname>Zougman</surname><given-names>A.</given-names></name><name><surname>Nagaraj</surname><given-names>N.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Universal sample preparation method for proteome analysis</article-title>. <source>Nat. Methods</source>
<volume>6</volume>, <fpage>359</fpage>&#8211;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1322</pub-id><?supplied-pmid 19377485?><pub-id pub-id-type="pmid">19377485</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y. Y.</given-names></name><name><surname>Mei</surname><given-names>Z. Q.</given-names></name><name><surname>Wu</surname><given-names>J. W.</given-names></name><name><surname>Wang</surname><given-names>Z. X.</given-names></name></person-group> (<year>2008</year>). <article-title>Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38&#945; in different phosphorylation states</article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>26591</fpage>&#8211;<lpage>26601</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M801703200</pub-id><?supplied-pmid 18669639?><pub-id pub-id-type="pmid">18669639</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>AD</term><def><p>Alzheimer's disease</p></def></def-item><def-item><term>SILAC</term><def><p>stable isotope labeling with amino acids in cell culture</p></def></def-item><def-item><term>A&#946;</term><def><p>amyloid &#946;</p></def></def-item><def-item><term>NFTs</term><def><p>neurofibrillary tangles</p></def></def-item><def-item><term>MS</term><def><p>mass spectrometry</p></def></def-item><def-item><term>LC-MS/MS</term><def><p>liquid chromatography-tandem mass spectrometry</p></def></def-item><def-item><term>FC</term><def><p>fold change</p></def></def-item><def-item><term>FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term>FASP</term><def><p>filiter-aided sample preparation method</p></def></def-item><def-item><term>HPLC</term><def><p>high-performance liquid chromatography</p></def></def-item><def-item><term>QE</term><def><p>Q Exactive</p></def></def-item><def-item><term>HF</term><def><p>Q Exactive HF</p></def></def-item><def-item><term>GO</term><def><p>Gene Ontology</p></def></def-item><def-item><term>Ab vs. Con</term><def><p>A&#946;<sub>25&#8722;35</sub>/Control</p></def></def-item><def-item><term>GF vs. Con</term><def><p>(A&#946;<sub>25&#8722;35</sub>+GFKP-19)/Control</p></def></def-item><def-item><term>GF vs. Ab</term><def><p>(A&#946;<sub>25&#8722;35</sub>+GFKP-19)/A&#946;<sub>25&#8722;35</sub></p></def></def-item><def-item><term>NOS</term><def><p>nitric oxide synthase</p></def></def-item><def-item><term>ASPP2</term><def><p>apoptosis-stimulating protein of p53</p></def></def-item><def-item><term>PP1</term><def><p>protein phosphatase 1</p></def></def-item><def-item><term>PP2B</term><def><p>protein phosphatase 2B</p></def></def-item><def-item><term>FYN</term><def><p>tyrosine-protein kinase</p></def></def-item><def-item><term>MARK</term><def><p>microtubule-associated protein/microtubule affinity-regulating kinase</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen-activated protein kinase.</p></def></def-item></def-list></glossary></back></article>